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Background: Globally, metabolic abnormalities affect at least 20-25% of the adult 
population; active TB disease is the ninth leading cause of death. Our overall goal was 
to assess key human host factors, including vitamin D and the gut microbiome, which 
affect this dual burden and have bi-directional effects on inflammation. Specifically, our 
objectives were to:  
1) assess the predictive performance of common anthropometric cut-offs utilized 
in diabetes population screening;  
2) examine the association between vitamin D and metabolic indicators;  
3) assess gut microbiota differences based on serum 25-hydroxyvitamin D 
(25[OH]D) status;  
among a population with a high prevalence of suspected or confirmed active TB disease 
and low or normal body mass index (BMI). 
Methods: At a rural hospital in South India, adult outpatients were enrolled after 
providing informed consent. Data collection included interviews, clinical examinations, 
anthropometry, and biological samples. Three study participant subsets were included 
 in different analyses. Cornell University and the hospital institutional review boards 
approved study protocols. 
Results: Most study participants had BMI <25 kg/m2 (88.2%) or waist circumference 
(WC) < diabetes screening cut-offs among South Asian populations (79.3%), which 
would be considered low risk in diabetes screening. However, one-third of study 
participants either had glycated hemoglobin (HbA1c) ≥ 6.5% (12.3%) or between 5.7% 
and <6.5% (20.3%). BMI ≥25.0 kg/m2 demonstrated low sensitivity (0.21; 95% CI: 0.06, 
0.35) as a screening indicator for HbA1c ≥ 6.5%. Median 25(OH)D was 51.8 nmol/L 
(IQR 36.0-70.0). Serum 25(OH)D was inversely associated with glycated hemoglobin 
and WC (both p<0.05), respectively, though not hypertension or gut microbiota 
diversity (all p>0.05). Most bacterial sequences in rectal swab samples were from the 
Firmicutes and Bacteroidetes phyla. 
Conclusions: Our findings indicate a high prevalence of elevated HbA1c (≥ 5.7%), and 
suggest the need for population-specific BMI and WC cut-offs in diabetes screening. 
Vitamin D status was associated with HbA1c, however not gut microbiome diversity. 
Further studies are needed to elucidate the potential roles of vitamin D and the gut 
microbiome in mitigating the dual burden of metabolic abnormalities and active TB 
disease among populations with low BMI in resource-limited settings. 
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CHAPTER I: A brief literature review of the dual burden of disease from 
metabolic abnormalities and tuberculosis among populations with a high 
prevalence of low body mass index 
 
Overview 
The overarching goal of this dissertation was to elucidate the dual burden of disease 
from active tuberculosis (TB) disease and metabolic abnormalities such as elevated 
glycated hemoglobin and abnormal blood pressure among populations that 
predominantly have low body mass index (BMI; <25 kg/m2; Chapter I). This included 
assessing key human host factors, including micronutrient status (vitamin D) and the 
gut microbiome, which have bi-directional effects on inflammation.  
 
Specifically, the objectives were to: 
1) Examine how common anthropometry-based (waist circumference, BMI) 
population screening cut-offs for diabetes and pre-diabetes perform compared 
to laboratory assays (Chapter II); 
2) Assess the association between vitamin D and metabolic abnormalities (Chapter 
III); and 
3) Characterize the gut microbiome (composition, diversity) and compare 
differences by serum 25-hydroxyvitamin D concentration (Chapter IV); 
among a clinical population with a high prevalence of suspected or confirmed active TB 
disease and low BMI (Figure 1) in South India.  
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Figure 1. Potential pathways involving inflammation in the dual burden of metabolic abnormalities and  
active tuberculosis disease  
 3 
Dual burden from metabolic abnormalities and tuberculosis 
Metabolic disorders and abnormalities affect 20-25% of adults globally [1]. Metabolic 
syndrome, a cluster of metabolic abnormalities including central adiposity and blood 
pressure, is associated with a three-fold increased risk of diabetes and two-fold 
increased risk of cardiovascular diseases [1]. Annually, 17.5 million deaths are related 
to cardiovascular diseases [2]; and 1.5 million deaths are caused by diabetes [3]. Four 
hundred and twenty-two million people have diabetes currently; the number of 
individuals with diabetes has quadrupled since 1980 [3]. In India, the prevalence of 
diabetes is 9.1% among adults between 20-79 years, which is equivalent to more than 
66 million adults [4]. 
 
Globally, active TB disease is the ninth leading cause of death, and also the single 
infectious agent that causes the most number of deaths [5]. There were an estimated 
10.4 million incident active TB disease cases in 2016 [5]. India had a 37% increase of 
incident active TB cases between 2013 and 2016 [5]. 
 
At the population-level, many geographic regions have the dual burden of disease from 
metabolic abnormalities as well as TB (active TB disease, latent TB infection) [3, 5]. 
Moreover, there has been an observed synergistic interaction: 1) diabetes is associated 
with a three-fold increased risk of active TB disease; 2) active TB disease is associated 
with a higher prevalence of diabetes and impaired glucose tolerance [6]. However, a 
key research gap is elucidating how to mitigate the dual burden of disease from 
metabolic abnormalities and active TB disease at the individual-level. 
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Among populations with a high prevalence of low body mass index 
At the individual-level, one major challenge is the early detection and treatment of 
metabolic abnormalities, given that metabolic abnormalities differ among populations 
with low BMI [7-18]. Central adiposity and visceral fat are more strongly associated 
with insulin resistance and type 2 diabetes mellitus, compared to overall obesity [7-10]. 
As an example, compared to Caucasian populations, Asian populations have a greater 
tendency for central fat accumulation [19] and also a higher risk for T2DM at a lower 
BMI [15-18]. Another study found that reduction of body mass (from gastric bypass) 
was associated with higher brown and beige adipose tissue activity with cold exposure 
[20]. 
 
Certain fat tissues have higher proportions of brown or beige (synonymously inducible, 
brown-in-white, brite) adipocytes, while other fat tissues have greater percentage of 
white adipocytes (including visceral fat) [21-23]. White, brown, and beige adipocytes 
differ in terms of phenotype and functionality [23-28], including metabolism [21-23]. 
Brown (or beige) adipocytes are involved in thermogenesis via the mitochondrial 
uncoupling protein (thermogenin) [21-23]. Furthermore, studies have shown that brown 
adipocytes are protective against T2DM indicators and associated with lower BMI [22, 
29]. In contrast, white adipocytes were associated with visceral fat, which is linked with 
a higher risk of insulin resistance and thus, diabetes [30]. Given prior evidence, one key 
research questions is: Should recommendations for the screening and prevention of 
metabolic abnormalities differ in populations with low BMI (Chapter II)? 
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Role of inflammation 
Inflammation is closely interrelated to metabolic function and regulation [31], as well 
as the host immune response to Mycobacterium tuberculosis (M. tb) [32]. A major 
research gap is understanding how to support the critical balance of pro- and anti-
inflammatory responses [31]. This encompasses understanding the potential roles of key 
human host factors, including nutritional status (e.g. micronutrients [vitamin D]) and 
the gut microbiome, which have been shown to have bi-directional interactions with 
inflammation [33]. 
 
Vitamin D 
Vitamin D is a steroid hormone that is consumed (diet, supplements) and endogenously 
produced through photochemical synthesis after sunlight exposure (ultraviolet rays) 
[34]. Vitamin D is converted to the major circulating form (25-hydroyxvitamin D; 
25[OH]D) by a cytochrome P450-based hydroxylase (CYP) 2R1 in the liver; and then 
to the active form (1,25-dihydroxyvitamin D; 1,25[OH]2D) by CYP27B1 in the kidney 
[34]. Subsequently, 1,25(OH)2D has genomic and non-genomic effects, which affect 
skeletal and potentially extraskeletal health outcomes [34-41]. Vitamin D is anti-
inflammatory and an immunoregulator [42-48], including in the context of metabolic 
abnormalities (Chapter III) as well as active TB disease (Chapter IV), respectively [33, 
49].  
 
In terms of metabolic abnormalities, vitamin D has been observed to affect energy 
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homeostasis (including glucose metabolism), body composition, and blood pressure 
[34, 50]. Potential mechanisms include: 1) Vitamin D receptors (VDRs; nuclear 
hormone receptors) and binding proteins (DBPs) are in pancreatic tissues [34]. 2) 
Vitamin D deficiency causes increased phosphorous and reduced calcium, which 
increases parathyroid hormone [34]. Secondary hyperparathyroidism causes abnormal 
glucose metabolism [34]. 3) Active vitamin D (1,25[OH]2D) regulates adipocyte 
metabolism, including adipogenesis and apoptosis [34]. 4) Active vitamin D has been 
demonstrated to decrease renin gene expression, which affects the renin-angiotensin-
aldosterone system and could regulate blood pressure [51-54]. Observational human 
studies have found inverse associations between suboptimal vitamin D status and 
glycated hemoglobin (HbA1c) (Table 1) as well as increased type 2 diabetes mellitus 
[55-58], insulin resistance [59]; and reduced insulin sensitivity [60, 61]. Most cross-
sectional studies showed an inverse association between low 25(OH)D serum (or 
plasma) concentration and greater waist circumference (Table 2) [62-70]. Based on 
meta-analyses, vitamin D (25(OH)D) was protective against high blood pressure in two 
meta-analyses (Table 3) [71, 72]; several found null findings [73-76]. Despite the 
previous evidence, there are limited studies among individuals with low BMI and 
residing in resource-limited settings (Chapter III).  
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Table 1. Studies assessing the association between vitamin D and glycated hemoglobin a 
Study Design Sample Size Study Population Location Exposure Outcome Key Findings Ref 
Biomarker Biological Sample Assessment Method 
Cross-sectional 127 Children, adolescents with 
high BMI (>95th percentile for 
age) 
United States 25(OH)D (nmol/L) Serum RIA HbA1c (%) • Serum 25(OH)D inversely correlated 
with HbA1c (r=-0.23, p<0.01) 
[50] 
Cross-sectional 124 Patients with T2DM Jordan 25(OH)D (nmol/L) Serum LC-MS/MS HbA1c (%) • 25(OH)D (log) inversely correlated with 
HbA1c  
[52] 
Cross-sectional 216 Adults at 20 clinics United Arab 
Emirates 
25(OH)D (nmol/L) Serum Multiple HbA1c (%) • HbA1c ≥6.5% associated with 25(OH)D 
≤30 nmol/L 
[53] 
Cross-sectional 524 Patients with high BMI (≥ 35 
kg/m2) 
Italy 25(OH)D (ng/mL) Blood Autoanalyzer HbA1c (%) • 25(OH)D inversely associated with 
HbA1c (ß=-0.10; p<0.05) 
[54] 
Cross-sectional 1,175 Patients with T2DM Korea 25(OH)D (ng/mL) Serum LC-MS/MS HbA1c (%) • Mean HbA1c inversely associated with 
25(OH)D 
[55] 
Cross-sectional 160 Pregnant women (3rd 
trimester) 
Egypt 25(OH)D (nmol/L) Serum RIA HbA1c (%) • Inverse correlation of HbA1c and 
25(OH)D (r=-0.49; p<0.05) 
[56] 
Cross-sectional 4,391 Adults (>18 years) with high 
BMI (obese) 
Iran 25(OH)D (ng/mL) Serum RIA HbA1c (%) • Serum 25(OH)D inversely associated 
with HbA1c 
[57] 
Cross-sectional 4,591 Adults United States 25(OH)D (ng/mL) Blood CLIA HbA1c (%) • Deficient 25(OH)D associated with 
increased odds of elevated HbA1c (OR 
2.47 [95% CI: 1.95, 3.13] 
[58] 
Cross-sectional 1,941 Adolescents (12-17 years) United States 25(OH)D (nmol/L) Serum RIA HbA1c (%) • No significant association between 
25(OH)D and HbA1c 
[71] 
Cross-sectional 84 Patients at diabetes clinic with 
BMI between 18.5-29.9 kg/m2 
Iran 25(OH)D (ng/mL) Serum ELISA HbA1c (%) • 25(OH)D not associated with HbA1c 
(%) 
[72] 
Cross-sectional 2,038 Adults (≥ 65 years) United 
Kingdom 
25(OH)D (nmol/L) Serum RIA HbA1c (%) • HbA1c (≥ 6.5%) was independently 
associated with low vitamin D levels 
(25[OH]D  <25.0 nmol/L; OR 2.30 
[95% CI 1.20, 4.42]) 
 
[59] 
Cross-sectional 60 Adults (18-80 years) with DM 
and stage 1-4 CKD 
Canada 25(OH)D, 
1,25(OH)2D 
(nmol/L) 
Serum LC-MS/MS HbA1c (%) • No association between vitamin D 
(25(OH)D, 1,25(OH)2D) and HbA1c (≥ 
7.0%) 
[73] 
Cross-sectional 3.520 Individuals with HbA1c 
between 5.8-6.9% 
Norway 25(OH)D (nmol/L) Serum LC-MS/MS HbA1c (%) • HbA1c (%) differed across 25(OH)D 
quartile 
[60] 
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Cross-sectional 8.643 Adults (30-87 years) 
 
Norway 25(OH)D (nmol/L) Serum ECLIA HbA1c (%) • 25(OH)D and HbA1c (%) were 
correlated (p<0.01) 
[157] 
Cross-sectional 7,189 Adults (45 years; born in 1st 
week of March, 1958) 
England, 
Scotland, Wales 
25(OH)D (nmol/L) Serum Enzyme immunoassay HbA1c (%) • 25(OH)D associated with HbA1c [158] 
Cross-sectional 141 Patients with T2DM Pakistan 25(OH)D (ng/mL) Serum, plasma Immunoassay HbA1c (%) • 25(OH)D (<20 ng/mL) associated with 
HbA1c >7.0% 
[61] 
Cross-sectional 8.655 Non-institutionalized civilian 
individuals 
United States 25(OH)D (nmol/L) Serum RIA HbA1c (%) • 25(OH)D inversely associated with 
HbA1c (%) 
[62] 
Cross-sectional 245 Patients with T2DM and 
metformin medication 
France 25(OH)D (ng/mL) Plasma CLIA HbA1c (%) • Mean HbA1c (%) differed by 25(OH)D 
status (sufficiency ≥ 30 ng/mL, 
insufficiency 21-29 ng/mL, deficiency ≤ 
20 ng/mL; p<0.01) 
[159] 
Cross-sectional 15,169 Adults (>20 years) without 
diabetes 
Korea 25(OH)D (ng/mL) Serum RIA HbA1c (%) • 25(OH)D was not correlated with 
HbA1c (p>0.05) 
[74] 
Cross-sectional 9,773 Adults (≥ 18 years) United States 25(OH)D (ng/mL) Serum RIA HbA1c (%) • 25(OH)D inversely associated with 
HbA1c (p<0.01) 
[63] 
Cross-sectional 477 Patients with DM United States 25(OH)D (ng/mL) Serum RIA HbA1c (%) • Vitamin D insufficiency (<20 ng/mL) 
associated abnormal HbA1c (OR 1.56 
[95% CI 1.03, 2.37]; ≥ 6.5%) 
[160] 
Cross-sectional 120 Patients with T2DM Greece 25(OH)D (ng/mL) Serum, plasma RIA HbA1c (%) • 25(OH)D inversely associated with 
HbA1c (%) overall (and in stratified 
groups of DM patients and controls; 
p<0.01) 
[64] 
Cross-sectional 147 Pregnant women in third 
trimester and attending 
gestational DM clinic 
Australia 25(OH)D (nmol/L) Serum RIA HbA1c (%) • 25(OH)D inversely associated with 
HbA1c (%) among women with GDM 
[65] 
Cross-sectional 100 Patients with T2DM and CKD 
(stages 3-4) 
Malaysia 25(OH)D (nmol/L) Serum CLIA HbA1c (%) • Each decrease of 10-nmol/L in serum 
25(OH)D associated with 0.2% HbA1c 
increase 
[66] 
Cross-sectional 3,210 Adults (50-70 years) China 25(OH)D (nmol/L) Plasma RIA HbA1c (%) • Vitamin D modified the effect of 
rs6902123 (SNP of PPAR-delta gene) 
on HbA1c (p for interaction = 0.0347) 
[161] 
Cross-sectional 109 Chinese patients with T2DM Australia 25(OH)D (nmol/L) Blood Nicoll’s method HbA1c (%) • Hypovitaminosis D not associated with 
HbA1c 
[75] 
Cross-sectional 1,139 Adults (Malays, Chinese, 
Indians) 
Singapore 25(OH)D (ng/mL) Serum ECLIA HbA1c (%) • HbA1c (%) associated with suboptimal 
25(OH)D concentration (<30 ng/mL; 
p<0.05) 
[162] 
Cross-sectional 250 Adults with high BMI 
(overweight, obese) 
New Zealand 25(OH)D (nmol/L) Serum RIA HbA1c (%) • Inverse association between 25(OH)D 
and HbA1c (%; r=-0.16; p=0.01) 
[67] 
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Cross-sectional 63 Patients with T2DM Spain 25(OH)D (nmol/L) Serum EIA HbA1c (%) • Improved HbA1c (9.4% versus 7.3%) 
associated with decreased 25(OH)D 
(72.7 nmol/L to 59.0 nmol/L; p<0.05) 
[163] 
Cross-sectional 606 Patients with T2DM, pre-
diabetes, or normal glucose 
tolerance 
India 25(OH)D (ng/mL) Serum Chemiluminescence HbA1c (%) • No association between vitamin D 
deficiency (<30 ng/mL) and HbA1c (%) 
[76] 
Cross-sectional 2,877 Inuit adults Greenland 25(OH)D (nmol/L) Serum LC-MS/MS HbA1c (%) • Increasing 25(OH)D (per 10 nmol/L) 
associated with HbA1c (0.39%; p<0.01) 
[164] 
Cross-sectional 121 Children and adolescents (11-
21 years) treated for T1DM 
and T2DM 
United States 25(OH)D (ng/mL) Blood CLIA HbA1c (%) • Patients with T2DM (but not T1DM) 
had an inverse association between 
HbA1c and 25(OH)D 
[68] 
Cross-sectional 128 Patients with T2DM Turkey 25(OH)D (ng/mL) Blood Multiple HbA1c (%) • 25(OH)D < 20 ng/mL not associated 
with HbA1c >7% (p>0.05) 
[77] 
Cross-sectional 280 Individuals without diabetes 
and older 
Netherlands 25(OH)D (nmol/L) Blood RIA HbA1c (%) • 25(OH)D not associated with follow-up 
HbA1c (beta coefficient -0.09, p>0.05) 
[165] 
Cross-sectional 141 Patients with T1DM (>12 
months after diagnosis) 
Italy 25(OH)D (nmol/L) Serum CLIA HbA1c (%) • 25(OH)D inversely associated with 
HbA1c (p<0.01) 
[69] 
Cross-sectional 286 Study participants without DM 
history 
Italy 25(OH)D (ng/mL) Plasma CL microparticle IA HbA1c (%) • HbA1c between 5.7-6.4% associated 
with 25(OH)D 
[166] 
Cross-sectional 715 Patients with T2DM Italy 25(OH)D (ng/mL) Serum CLIA HbA1c (%) • Serum 25(OH)D inversely associated 
with HbA1c (r=-0.12, p<0.01) 
[70] 
Prospective cohort 
study 
6,565 Volunteer study participants Canada 25(OH)D (nmol/L) Serum CLIA HbA1c (%) • Compared to those without 25(OH)D 
nmol/L increase during follow-up, those 
with a 25(OH)D nmol/L increase ≥50 
nmol/L were 0.74 times more likely to 
have elevated HbA1c (p=0.03) 
[78] 
Prospective cohort 
study 
197 Pregnant women Thailand 25(OH)D (ng/mL) Plasma --- b HbA1c (%) • HbA1c independently associated with 
low 25(OH)D ng/mL among women 
with GDM (n=70) 
[167] 
Prospective cohort 
study 
266 Pregnant women (24-28 weeks 
gestation) screened for GDM 
Spain 25(OH)D (ng/mL) Serum --- b HbA1c (%) • Inverse correlation between 25(OH)D 
and HbA1c 
[79] 
Prospective cohort 171 Children and adolescents with 
T2DM 
Turkey 25(OH)D (ng/mL) Plasma LC-MS/MS HbA1c (%) • Vitamin D deficiency (<20 ng/mL) 
associated with HbA1c (p<0.05) 
[168] 
Retrospective 
cohort study 
191 Patients with high BMI 
(obese) 
United States 25(OH)D (ng/mL) Serum LC-MS/MS HbA1c (%) • 25(OH)D inversely associated with 
HbA1c 
[80] 
Retrospective 
cohort study 
301 Children, adolescents with 
T1DM 
Saudi Arabia 25(OH)D (nmol/L; 
≤37.5 nmol/L) 
Serum HPLC HbA1c (%) • No correlation between HbA1c and 
vitamin D deficiency 
[169] 
 10 
Retrospective 
cohort study 
1,074 Men at outpatient clinics United States 25(OH)D (ng/mL) Serum CLIA HbA1c (%) • 25(OH)D inversely associated with 
HbA1c among African American men, 
though not Caucasian American men 
[81] 
Retrospective 
cohort study 
110 Post-menopausal women with 
T2DM 
Mexico 25(OH)D (ng/mL) Serum LC-MS/MS HbA1c (%) • No significant linear relationship 
between HbA1c and 25(OH)D (p>0.05) 
[170] 
Case control study 129 Patients with T2DM (n=69); 
matched controls (n=60) 
Kuwait 25(OH)D (nmol/L) Serum HPLC HbA1c (%) • No association between 25(OH)D and 
HbA1c 
[171] 
Case control study 50 Male patients with (n=30) or 
without T2DM (n=20; age- 
and socioeconomic status-
matched) 
Egypt 25(OH)D (ng/mL) Serum RIA HbA1c (%) • Serum 25(OH)D inversely associated 
with HbA1c (p<0.05) 
[82] 
Case control study 100 Adolescents with T1DM 
(n=60) or controls (n=40) 
Poland 25(OH)D (ng/mL) Serum ECLIA HbA1c (%) • Among those with T1DM, low 
25(OH)D negatively correlated with 
HbA1c (r=-0.43, p<0.01) 
[83] 
Case control study 436 Patients with T2DM (n=276) 
and controls (n=160) 
Korea 25(OH)D (ng/mL) Serum CLIA HbA1c (%) • High HbA1c associated with 25(OH)D 
<20 ng/mL 
[84] 
Nested case control 
(in intervention) 
160 Patients with intervention 
(Vitamin D3 supplement of 
20,000 IU twice weekly for 6 
months) 
Norway 25(OH)D (nmol/L) Serum LC-MS/MS HbA1c (%) • High 25(OH)D associated with lower 
HbA1c 
[85] 
Intervention 80 Patients with T1DM and 
25(OH)D <50 nmol/L at 
baseline with intervention 
(4000 IU vitamin D; 1200 mg 
calcium intake) 
Saudi Arabia 25(OH)D (nmol/L) Serum CPBA HbA1c (%) • Significant difference in mean HbA1c 
(%) between vitamin D status groups at 
study endline (25[OH]D <35.4, ≥35.4-
51, >51.0 nmol/L; p=0.02) 
[172] 
Intervention 840 Patients with intervention 
(Vitamin D2 supplement of 
50,000 IU/week for 8 weeks) 
United States 25(OH)D (ng/mL) Serum Multiple HbA1c (%) • 25(OH)D inversely associated with 
HbA1c (r=-0.29; p=0.03) 
[173] 
a PubMed search strategy was based on the following terms: “("vitamin d"[MeSH Terms] OR "vitamin d"[All Fields] OR "ergocalciferols"[MeSH Terms] OR "ergocalciferols"[All Fields]) AND 
("hemoglobin a, glycosylated"[MeSH Terms] OR "glycosylated hemoglobin a"[All Fields] OR "hba1c"[All Fields])“ and restricted by publication date (on or prior to October 1, 2017). 
Exclusion criteria included: 1) not primary data source (including reviews, editorials); 2) no measurement of glycated hemoglobin; 3) no assessment of vitamin D status in blood; 4) no humans. 
Among the 379 studies initially identified, 52 studies were within the scope of this review and included. 
b Only abstract accessed; information not available in abstract 
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Table 2. Studies assessing the association between vitamin D and waist circumference a 
Study Design Sample Size Study Population Location Exposure Outcome Key Findings Ref 
Biomarker Biological Sample Assessment Method 
Cross-sectional 87 Healthy female study 
participants 
Saudi Arabia 25(OH)D (ng/mL) Plasma HPLC Waist circumference • 25(OH)D negatively associated with waist 
circumference 
[100] 
Cross-sectional 1,205 Adults (18-80 years) Qatar 25(OH)D (ng/mL) Serum CLIA Waist circumference • Waist circumference associated with 
vitamin D deficiency (20 ng/mL) 
[101] 
Cross-sectional 1,361 Adolescents Malaysia 25(OH)D (nmol/L) Serum ECLIA Waist circumference • Greater waist circumference associated with 
vitamin D deficiency (OR 2.64 [95% CI 
1.65, 4.25]) 
[102] 
Cross-sectional 62 Postmenopausal women Rome 25(OH)D (ng/mL) Serum HPLC Waist circumference • 25(OH)D correlated with waist 
circumference (r=-0.54, p<0.01) 
• Adjusted for covariates, 25(OH)D not 
associated with waist circumference 
[103] 
Cross-sectional 255 Infants (9 months) Denmark 25(OH)D (nmol/L) Plasma CLIA Waist circumference • 25(OH)D negatively associated with waist 
circumference (p<0.01) 
[104] 
Cross-sectional 570 Outpatients with T2DM 
(n=420) and non-diabetic 
obese (n=150) 
Italy 25(OH)D (ng/mL) Serum CLIA Waist circumference • 25(OH)D (age-adjusted) was inversely 
associated with WC (p<0.01) in both 
genders 
[105] 
 
Cross-sectional 100 Renal transplant recipients 
without diabetes 
Brazil 25(OH)D (ng/mL) Serum CLIA Waist circumference • Median waist circumference higher in the 
group with vitamin D deficiency  
[106]  
Cross-sectional 2,096 Participants from two other 
completed clinical trials of 
neoplasia 
United States 25(OH)D (ng/mL) Blood CLIA Waist circumference • 25(OH)D inversely associated with waist 
circumference (p trend <0.04) 
[107]  
Cross-sectional 435 Prepubertal children (~7 
years) 
Chile 25(OH)D (ng/mL) Serum CLIA Waist circumference • 25(OH)D < 30 ng/mL associated with high 
waist circumference ≥ 75th percentile 
among girls (OR 2.4 [95% CI 1.4, 4.3]) and 
boys (OR 2.2 [95% CI 1.2, 4.0]) 
[108] 
 
Case-control 335 Asian Indians: 162 NAFLD 
cases, 173 controls (age- and 
sex-matched) 
India 25(OH)D (ng/mL) Serum RIA Waist circumference • Lowest quartile of 25(OH)D associated 
with high waist circumference 
[174] 
 
a The studies in this table were identified from a PubMed search strategy was based on the following terms: “("vitamin d"[MeSH Terms] OR "vitamin d"[All Fields] OR "ergocalciferols"[MeSH 
Terms] OR "ergocalciferols"[All Fields]) AND ("waist circumference"[MeSH Terms] OR ("waist"[All Fields] AND "circumference"[All Fields]) OR "waist circumference"[All Fields])” and 
restricted by publication date (on or prior to October 9, 2017). Exclusion criteria included: 1) no waist circumference measurement; 2) no assessment of vitamin D status in blood or vitamin D 
supplementation; 3) no humans; 4) not systematic review and/or meta-analyses; 5) not in English language. 
b RCT unless otherwise noted 
c Range unless otherwise noted 
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Table 3. Reviews assessing the association between vitamin D and hypertension a 
Exposure # of RCTs b # of Study Participants Study Population Follow-Up 
(months) c 
Outcome(s) Key Findings Ref 
Vitamin D status 10 prospective 
studies 
58,262 Healthy, disease states 1.3-15 Hypertension • Reduced risk of incident hypertension (RR 0.76 [95% CI 0.63, 
0.90]) among those in top (versus bottom) category of 
25(OH)D 
[113] 
19 cross-
sectional 
studies 
90,535 --- • Reduced odds of hypertension (OR 0.79 [95% CI 0.73, 0.87]) 
among those in top (versus bottom) category of 25(OH)D 
Vitamin D status 3 cohorts 3,295 Healthy, disease states 364-416 Hypertension • Lower 25(OH)D associated with incidence hypertension (RR 
1.8 [95% CI 1.3, 2.4]) 
[114] 
Vitamin D 
supplementation 
10 37,162 Healthy, disease states (HTN, heart 
failure, T2DM, overweight and obesity) 
1-364 Blood pressure • Vitamin D supplementation reduced systolic blood pressure 
(weighted mean difference -1.9 mm Hg [95% CI -4.2, 0.4 mm 
Hg]) but did not change diastolic blood pressure 
Vitamin D 
supplementation 
8 917 Non-CKD, pre-HTN, HTN, African 
Americans 
3-84 Hypertension, blood pressure • No differences in systolic (-0.08 mm Hg, p=0.2) or diastolic 
(0.09 mm Hg, p=0.16) blood pressure among those with 
vitamin D supplementation, relative to placebo 
[115] 
Vitamin D 
supplementation 
46 4,541 Healthy, DM, HTN, older, CKD, HIV, 
HF 
1-18 Hypertension, blood pressure • No differences in systolic (-0.5 mm Hg, p=0.27) or diastolic 
(0.2 mm Hg, p=0.38) blood pressure among those with 
vitamin D supplementation, relative to placebo 
[116] 
Vitamin D 
supplementation 
14 751 patients, 767 controls Healthy, disease states (e.g. T2DM, 
osteoporosis, TB, obese or overweight) 
1-108 Blood pressure • No differences in systolic or diastolic blood pressure among 
those with and without vitamin D supplementation 
[117] 
Vitamin D 
supplementation 
30 4,744 Healthy, disease states Mean 5.6 (SD 
4.0) 
Blood pressure • No effect of vitamin D3 supplementation on systolic blood 
pressure (-0.68 mmHg, 95%CI: -2.19 to 0.84) and diastolic (-
0.57 mmHg, 95%CI: -1.36 to 0.22) 
• Subgroup analyses: Daily vitamin D3 supplementation (>800 
IU/day) for <6 months among individuals ≥ 50 years reduced 
systolic and diastolic blood pressure; vitamin D 
supplementation decreased systolic and diastolic blood 
pressure among those with low or normal BMI (not 
overweight or obese) 
[118] 
a The reviews and meta-analyses in this table were identified from a PubMed search strategy was based on the following terms: “(("vitamin d"[MeSH Terms] OR "vitamin d"[All Fields] OR 
"ergocalciferols"[MeSH Terms] OR "ergocalciferols"[All Fields]) AND ("hypertension"[MeSH Terms] OR "hypertension"[All Fields]) AND ("blood pressure"[MeSH Terms] OR ("blood"[All 
Fields] AND "pressure"[All Fields]) OR "blood pressure"[All Fields] OR "blood pressure determination"[MeSH Terms] OR ("blood"[All Fields] AND "pressure"[All Fields] AND 
"determination"[All Fields]) OR "blood pressure determination"[All Fields] OR ("blood"[All Fields] AND "pressure"[All Fields]) OR "blood pressure"[All Fields] OR "arterial pressure"[MeSH 
Terms] OR ("arterial"[All Fields] AND "pressure"[All Fields]) OR "arterial pressure"[All Fields] OR ("blood"[All Fields] AND "pressure"[All Fields]))) AND Review[ptyp]” and restricted by 
publication date (on or prior to October 9, 2017). Exclusion criteria included: 1) no blood pressure measurement; 2) no assessment of vitamin D status in blood or vitamin D supplementation; 3) 
no humans; 4) not systematic review and/or meta-analyses; 5) not in English language. 
b RCT unless otherwise noted 
c Range unless otherwise noted 
 13 
While early studies indicated that vitamin D upregulated anti-microbial activities of M. 
tb-infected macrophages [77-79], more recent data suggest that the more biologically-
significant activity of vitamin D is the downregulation of the inflammatory response to 
M. tb [49] and anti-TB treatments [33]. A murine model demonstrated that dietary 
vitamin D3 attenuated the inflammatory response in mice, however did not affect M. tb 
bacterial burden [49]. In a longitudinal study among 95 patients with active pulmonary 
TB disease, vitamin D supplementation was associated with decreased proinflammatory 
cytokines and attenuated the suppressive effects from anti-TB treatment [33]. 
Additionally, vitamin D supplementation was associated with faster sputum smear 
conversion [33]. 
 
Gut microbiome 
The human microbiome is defined as the ecological community of (commensal, 
symbiotic, pathogenic) microorganisms residing in our body space [80]. The gut 
microbiome has bi-directional effects on inflammation, including in the context of 
metabolic abnormalities and active TB disease [81-85]. Certain gut bacteria species 
produce short-chain fatty acids, including butyrate [81]. Butyrate is a microbial 
fermentation product, which has been demonstrated to regulate T regulatory (Treg) cell 
differentiation [86]. Treg cells have an essential role in immunological homeostasis 
through maintaining peripheral tolerance and controlling inflammation [87]. Butyrate-
producing bacteria (e.g. Roseburia intestinalis, Faecalibaterium prausnitzii) were lower 
among individuals with T2DM in one study [81]. Conversely, dysbiotic intestinal 
bacterial species are hypothesized to cause systemic metabolic endotoxemia, which 
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subsequently leads to metabolic inflammation, insulin resistance, and dyslipidemia [81-
84]. Prior studies found decreased gut microbiota diversity associated with active TB 
disease (and post-M. tb infection in mice) [88]. However preliminary evidence is 
limited, particularly among humans and in populations with low BMI (Chapter IV).  
 
Vitamin D regulates innate and adaptive immune responses [44, 78, 79, 89-93], 
including in the gastrointestinal tract and among intestinal microbiota [94-97]. 
Therefore, prior studies have assessed the interactions between vitamin D and the gut 
microbiome (Table 4) [94, 98]. Two murine studies demonstrated that VDR and 
CYP27B1 knockout mice had altered intestinal microbiota [94, 99]. Additionally, 
1,25(OH)2D treatment in CYP27B1 knockout mice was protective against colitis 
severity and decreased Helicobacteraceae in fecal samples [94]. Further studies among 
human populations are needed to confirm these findings (Chapter IV), and to assess the 
respective roles of different microbiomes (such as gut versus lung microbiome) as well 
as potential cross-talk between different microbiomes. 
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Table 4. Studies assessing the association between the gut microbiome and vitamin D (25[OH]D, VDR) a 
Study Design Sample Size Location Exposure Outcome Key Findings Ref 
Assessment Biological 
Specimen 
Microbial 
Assessment 
Method(s) 
Hypervariable 
Regions b 
Cases Controls 
Murine 
Models 
5 VDR-/- 
C57BL6 mice 
3 wild type 
C57BL6 mice 
Illinois, United 
States 
VDR knockout Bacterial 
abundance, 
functional 
pathways 
Fecal and cecal 
stool samples 
454 pyrosequencing V4-V6 • In fecal stool of VDR -/- mice, Lactobacillus 
decreased; Clostridium and Bacteriodetes increased 
• VDR -/- mice (vs WT):  Cecal microbiomes had 26 
increased and 14 decreased functional modules; fecal 
microbioms had 41 increased and 31 decreased 
functional modules (p<0.05) 
[140] 
 2 VDR-/-, 4 
CYP27B1 -/- 
C57BL6 mice 
2 wild type (for 
VDR -/-) and 4 (for 
CYP25B1 -/-) 
C57BL6 mice (age 
and sex matched) 
Pennsylvania, 
United States 
VDR, CYP27B1 
knockouts 
Bacterial 
abundance 
Fecal samples 454 pyrosequencing V3 • CYP and VDR -/- mice had increased bacteria in 
Bacteroidetes and Proteobacteria phyla; and decreased 
in Firmicutes and Defferibacteres phyla, compared to 
WT 
• CYP -/- mice had increased bacteria in 
Helicobacteraceae family, relative to WT 
• CYP and VDR -/- mice had higher number of bacteria 
in the Lactobacillaceae and Lachnospiraceae families, 
compared to WT 
[139] 
 
Cohort 
(GWAS) 
1,812 humans Kiel, Germany VDR gene Bacterial 
variation 
Fecal samples 16S rRNA 
sequencing 
V1-V2 • VDR gene associated with differences in overall 
microbial variation 
[155] 
Cross-sectional 150 young adults São Paulo, Brazil 25(OH)D 
concentration 
Bacterial 
composition 
Fecal samples 16S rRNA 
sequencing 
V4 • PCR, E-selectin; and abundances of Coprococcus and 
Bifidobacterium were inversely correlated with 
25(OH)D 
[175  
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Intervention 16 healthy humans Graz, Austria Vitamin D3 
supplementation 
(8 weeks; weekly 
dosage of 980 
IU/kg 
bodyweight) 
Bacterial 
composition 
7 sites (e.g. 
stomach, small 
bowel, colon, 
stool) 
16S rRNA 
sequencing 
V1-V2 • Vitamin D3 supplementation: Decreased relative 
abundance of Gammaproteobacteria (including 
Pseudomonas spp., Escherichia/Shigella spp.); 
increased bacterial richness  
• Increased CD8+ T cell fraction in terminal ileum 
• No changes in terminal ileum, appendiceal orifice, 
ascending colon, sigmoid colon, stools 
[176]  
a PubMed search strategy was based on the following terms: “("vitamin d"[MeSH Terms] OR "vitamin d"[All Fields] OR "ergocalciferols"[MeSH Terms] OR "ergocalciferols"[All Fields]) 
AND ("microbiota"[MeSH Terms] OR "microbiota"[All Fields] OR "microbiome"[All Fields])” and restricted by publication date (on or prior to October 1, 2017). Exclusion criteria included: 
1) not primary data source (including reviews, editorials); 2) no whole microbiome sequencing techniques; 3) no assessment of vitamin D status, genes involved in vitamin D metabolism (e.g. 
VDR, CYP27B1), or related intervention. Among the 134 studies initially identified, 5 studies were within the scope of this review and included. 
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ABSTRACT 
 
Background: Determining nutritional status among the source population is critical to 
the design and conduct of randomized controlled trials. This “phase 0” is necessary to 
evaluate the burden of disease and potential to benefit, and appropriately target 
interventions. 
Objective: Our study objective was to evaluate the nutritional profile of a clinical 
population in India, from which study participants will be recruited for a randomized 
controlled trial of vitamin D supplementation (ClinicalTrials.gov #: NCT01992263). 
Methods: In this cross-sectional study, nutritional status of outpatients (n=834) was 
assessed by biochemical indicators, anthropometry, and clinical examination during 
their hospital visit. Anemia was defined by hemoglobin, per World Health Organization 
recommendations. 
Results: Overall, 71.9% of study participants had anemia (females 82.1%, males 
68.2%); among these, 29.2% had hypochromia and microcytosis. Median 25-
hydroxyvitamin D was 51.5 nmol/L (IQR 36.6-69.6). Most study participants had low 
or normal body mass index (BMI; <25 kg/m2; 88.2%) or waist circumference (WC; < 
International Diabetes Federation diabetes screening cut-offs among South Asian 
populations; 79.3%), which would be considered low risk in diabetes screening. 
However, one-third of study participants either had glycated hemoglobin (HbA1c) ≥ 
6.5% (12.3%) or ≥ 5.7% and <6.5% (20.3%). BMI ≥25.0 kg/m2 demonstrated low 
sensitivity (0.21; 95% CI: 0.06, 0.35) as a screening indicator for HbA1c ≥ 6.5%. 
Conclusions: This “phase 0” investigation yielded three key findings: 1) Most 
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individuals had anemia but not microcytosis or hypochromia, indicators of iron 
deficiency. 2) Despite the median BMI of 18.8 kg/m,2 nearly one-third of study 
participants had HbA1c ≥ 5.7%. 3) Current population screening cut-offs (based on BMI 
or WC) demonstrated low sensitivity in pre-diabetes and diabetes screening, suggesting 
the need for population-specific cut-offs. These results indicate the suitability of this 
source population for a nutritional intervention trial, and facilitate intervention tailoring 
and identifying appropriate potential confounders for trial outcomes. 
 
Key words: Nutrition, vitamin D, micronutrients, anthropometry, assessment 
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INTRODUCTION 
One-third of the global population is estimated to be malnourished (1). Key 
interventions (2), a strategic framework (3), and goals (4, 5) were recently outlined to 
achieve improved nutrition, in order to support human health and development. Despite 
public health and policy efforts, numerous obstacles still impede our ability to 
effectively target malnutrition (1, 2, 4, 6).  
 
One major challenge is the need for comprehensive nutritional assessment to identify 
appropriate target populations for conducting intervention trials to establish efficacy and 
inform the development and scale-up of existing policies and programs. Defining the 
nutritional profile of the source population (7, 8) is a critical preparation step for 
intervention studies, in order to evaluate the suitability of study treatment regimens and 
the likelihood to benefit of potential study participants. Similarly, many global clinical 
and public health recommendations require information about the target population to 
inform implementation in specific settings.  
 
In this study, “source population” was defined as the underlying study population from 
which the participants will be recruited and enrolled in a randomized controlled trial (9). 
Many factors affect the question of whether study interventions are appropriate among 
a specific source population. These relate primarily to ethical considerations, 
characterization of disease burden, and biological plausibility and include: 
1) Ethical considerations: Will proposed interventions (dosage, duration, 
frequency) cause as minimal risks as possible for study participants (e.g., 
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avoiding toxicity and exceeding tolerable upper limits)? Is there a state of 
clinical equipoise? 
2) Characterization of disease burden: What is the prevalence of micronutrient 
deficiency in the source population? What is the burden of disease from 
related comorbidities? 
3) Biological plausibility: What is the potential to benefit among potential study 
participants? 
 
The goal of this study was to conduct a “phase 0” nutritional assessment of a clinical 
source population, from which study participants will be recruited and enrolled for a 
randomized controlled trial (RCT) of vitamin D supplementation in adults with active 
tuberculosis disease (ATBD) in southern India (ClinicalTrials.gov identifier: 
NCT01992263). The objectives were to assess the prevalence of malnutrition, based on 
biochemical (i.e., vitamin D, hemoglobin, anemia) and anthropometric indicators. We 
also evaluated the relative diagnostic performance of common anthropometric cut-off 
values (i.e., body mass index [BMI], waist circumference [WC]) in population-based 
screening for diabetes, given the increasing epidemiological and nutritional transition 
in similar low- and middle-income settings.   
 
 
METHODS 
Ethical conduct of research 
The study protocol was approved by the Institutional Review Board at Cornell 
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University, and the Institutional Ethics Committee at Arogyavaram Medical Centre. All 
study participants provided informed consent to participate prior to data collection. 
 
Study population 
This cross-sectional study was conducted at Arogyavaram Medical Centre in Andhra 
Pradesh, India. The clinic is part of a hospital with inpatient facilities, and regularly 
receives a number of patients with suspected or confirmed ATBD. Hospital physicians 
referred their patients to study staff. Study participants (n=834) were recruited and 
enrolled during their hospital visits between September 2014 and May 2016. Exclusion 
criteria were: age <18 years, severe illnesses or complications requiring hospitalization 
(i.e., apart from preventative tuberculosis control measures), and no hemoglobin data 
(Figure 2). 
 
Data collection 
Structured interviews were administered to collect sociodemographic, clinical, 
nutritional, and anthropometric data by trained research assistants in the local language, 
Telugu. Sociodemographic covariates included: age, sex, educational level, monthly 
household income, and cigarette use.  
 
Sputum and blood samples were collected from a subset of study participants (Figure 
2), based on clinical assessment by hospital physicians and standard of care. For ATBD 
assessment, patients were requested to provide a sputum sample at the time of his or her 
initial hospital visit, and a second sputum sample on the following morning. Trained  
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Figure 2. Study participant flow chart 
 
 
phlebotomists collected blood samples using standard clinical protocols. 
 
Laboratory analyses 
Each sputum sample was assessed for ATBD by the detection of standard acid-fast 
bacilli (AFB) with Ziehl-Neelsen staining and conventional light microscopy. Blood 
samples were assayed for glycated hemoglobin (HbA1c [%]) by high-performance 
liquid chromatography (D-10; Bio-Rad Laboratories, Hercules, California, United 
States [US]). Complete blood counts were assessed by an automated hematology 
analyzer (BC-2800; Mindray Bio-Medical Electronics Co., Ltd., Shenzhen, People’s 
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Republic of China). Serum 25-hydroxyvitamin D (25[OH]D) was assayed by 
chemiluminescence immunoassay (LIAISON; DiaSorin Inc., Stillwater, Minnesota, 
US). The chemiluminescence immunoassay instrument was operated by a laboratory 
that participated in the Vitamin D External Quality Assessment Scheme (DEQAS), 
which used National Institute of Standards and Technology (Department of Commerce, 
US) references. 
 
Anthropometry 
Anthropometric measurements were assessed, based on World Health Organization 
(WHO) recommendations and other commonly utilized methods (10, 11). Height, WC, 
mid-upper arm circumference (MUAC), and skinfold thickness were measured to the 
nearest 0.1 centimeter; weight was assessed to the nearest 0.1 kilogram. Biologically 
unlikely values were considered missing. Total body and trunk fat (kg) were assessed 
by bioelectrical impedance analysis (BC-418 MA; Tanita Corporation, Tokyo, Japan; 8 
electrode). 
 
Definitions 
Educational level was categorized based on self-reported completion of formal 
coursework (i.e., no formal education or illiterate; primary [grades 1-5], secondary 
[grades 6-12, including higher secondary], and any higher education [college, graduate, 
post-graduate]). Self-reported monthly household income was dichotomized as < 5000 
Indian rupees (INR) or ≥ 5000 INR ) (12). This cut-off was rounded from the cut-off of 
4860 INR, based on the estimated monthly consumption expenditure for a family of five 
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residing in a rural area (2011-2012 prices) and the national poverty line of India 
(Government of India, Planning Commission, 2014 Report) (12). Cigarette use was 
categorized as current, previous, or never. 
 
ATBD was defined as at least one positive AFB sputum smear result. This included 
patients with one positive AFB result (regardless of first or second sputum sample), as 
well as two positive AFB results, according to the standard ATBD diagnostic guidelines 
in India (13). HbA1c was categorized by common cut-off values (≥ 6.5%, ≥ 5.7% to < 
6.5%, and <5.7%) that are recommended for clinical diagnosis of diabetes and pre-
diabetes (14, 15). Low vitamin D status was defined with several cut-off values 
(25[OH]D <25.0 nmol/L (16), <40.0 nmol/L (17), <50.0 nmol/L (17, 18), <75.0 nmol/L 
(18)). 
 
Hemoglobin (g/L) was considered as continuous and categorical values (including 
quintiles). Anemia and severe anemia were defined by hemoglobin cut-offs, per WHO 
recommendations (Table 11 - Supplemental) (19). Hemoglobin was adjusted for 
smoking by subtracting 0.3 g/L among any individuals who self-reported as currently 
smoking (19). We also considered other factors that affect anemia (e.g. pregnancy, 
residential elevation above sea level, smoking) (19). However, no study participants 
self-reported pregnancy; and all study participants visited the hospital study site, which 
has an elevation that does not require altitude adjustment (19). 
 
Red blood cell morphology were categorized to assess abnormalities, which reflect 
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different causes of anemia and commonly assist in evaluating different types of anemia 
(20). Microcytosis (<80 femtoliters/cell) was defined as mean corpuscular volume 
(MCV; femtoliters/cell; Table 11 - Supplemental) (20). Mean corpuscular hemoglobin 
(MCH; picograms/cell) was categorized as hyper-, normo-, and hypochromia (Table 11 
- Supplemental) (20). Hypochromic microcytic anemia was defined by hemoglobin 
(men <130 g/L, women <120 g/L (19)) as well as MCV <80 femtoliters/cell and MCH 
<27 picograms/cell (Table 11 - Supplemental) (20). Elevated erythrocyte sedimentation 
rate (ESR; mm/hr) was categorized according to age- and sex-specific cut-off values 
(Table 11 - Supplemental) (21, 22). Biologically unlikely values were considered 
missing; these included outliers (<2.5th and >97.5th percentiles). 
 
Anthropometric measurements (BMI, WC) were considered as continuous and 
categorized variables. Body mass index was defined as per standard WHO cut-offs 
(underweight < 18.5 kg/m2; normal weight ≥ 18.5 and < 25.0 kg/m2; overweight ≥ 25.0 
and < 30.0 kg/m2; and obese ≥ 30.0 kg/m2) (11). Additionally, we considered BMI cut-
offs for Asian populations (≥ 18.5 to < 23.0 kg/m2; ≥ 23.0 to < 27.5 kg/m2; ≥ 27.5 kg/m2), 
based on a WHO expert consultation (23). Waist circumference was considered as a 
continuous variable and tertiles based on distribution in this population. Elevated waist 
circumference was also defined based on International Diabetes Federation (IDF) cut-
offs (men ≥90 cm, women ≥80 cm) recommended for individuals in South Asia (24). 
 
Statistical analyses 
Continuous variables were assessed for normality using the Shapiro-Wilk test. For 
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descriptive statistics, continuous variables were reported as medians (interquartile 
ranges [IQRs]); categorical variables were reported as percentages. Subgroup 
comparisons were based on tests for continuous (i.e., Kruskal-Wallis) and categorical 
variables (i.e., likelihood ratio test). Spearman’s rank correlation coefficients assessed 
the respective bivariate associations in preliminary analysis. 
 
We assessed associations with univariate and multivariate regressions (log-binomial and 
logistic for categorical outcomes of interest) with a complete case analysis approach. 
Associations between anthropometric screening indicators (BMI, WC) and HbA1c ³ 
6.5% were assessed by multivariate log-binomial regressions; key covariates (age, sex) 
were accounted for in these models.  
 
The association between anemia and ATBD was evaluated by multivariate logistic 
regressions. Confounding assessment was based on the Rothman and Greenland 
approach (9). Potential confounders were determined a priori from previous literature 
(9, 19, 25). Based on univariate logistic regressions between each covariate with a 
respective outcome of interest, we included all covariates with p<0.25 in initial full 
models (9); key independent variables and covariates (age, sex) remained in multivariate 
models regardless of p-values, according to prior literature. Variables with p<0.05 were 
retained in the final multivariate models, according to a backwards stepwise regression 
approach (9).  
The predictive performance of anthropometric screening indicators (i.e., BMI, WC; 
categorical variables) for elevated HbA1c (³ 6.5%) were assessed by sensitivity, 
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specificity, positive predictive value (PPV), negative predictive value (NPV), and 
receiver operating characteristic (ROC) curve analysis (26). Observed area under the 
ROC curves (AUCs) were compared to AUC for the null hypothesis (0.5), based on the 
contrast matrices of differences between the areas under the ROC curves 
(ROCCONTRAST in SAS statistical software) (27). We also examined the predictive 
performance of anthropometric screening indicators, considering a cut-off of HbA1c ³ 
5.7% as the outcome of interest. 
 
Statistical analyses were conducted with SAS statistical software (version 9.4; SAS 
Institute Incorporated, Cary, North Carolina). All comparisons were two-sided; and 
considered statistically significant with a value of 0.05.  
 
RESULTS 
Sociodemographic characteristics 
The median age of study participants was 48 years (IQR 35, 60; Table 5), including 
individuals ranging from 18 to 87 years of age. Almost three-fourths of study 
participants were male (n=610; Table 5). Over half of study participants (54.0%) had a 
self-reported monthly household income less than 5000 INR (Table 5).  
 
Clinical morbidities: elevated glycated hemoglobin, tuberculosis 
Overall, 12.3% of study participants had HbA1c ³ 6.5%; and 20.3% of participants had 
HbA1c ³ 5.7% and < 6.5% (Table 5). Median HbA1c was 5.4% (IQR 5.0, 5.8; Table 
5), and was not statistically different between men and women (p>0.05; Table 5). 
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Among study participants with AFB assessment (n=363), 24.2% had ATBD (Table 5). 
 
Biochemical indicators: vitamin D, anemia 
Among study participants, median serum 25(OH)D concentration was 51.5 nmol/L 
(IQR 36.6-69.6; Table 6). The prevalence of low vitamin D ranged between 9.6-80.9%, 
depending on the 25(OH)D cut-off values: 80.9% (< 75.0 nmol/L), 47.1% (<50.0 
nmol/L), 30.2% (<40.0 nmol/L), and 9.6% (<25.0 nmol/L) of study participants had low 
vitamin D status (Table 6). 
 
Median hemoglobin concentrations were 115.0 g/L (IQR 99.0, 129.7; Table 6). A total 
of 71.9% of study participants (n=600) had anemia, and 6.4% had severe anemia (n=53; 
Table 6). The prevalence of anemia was 82.1% in women (n=184), and 68.2% in men 
(n=416; Table 6). Approximately a quarter of study participants had microcytosis 
(n=203), and none had macrocytosis. Nearly half of study participants were 
hypochromic (48.0%). A total of 59.0% of study participants had elevated ESR (n=492; 
median 30 mm/hr; IQR 15, 55; Table 6). 
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Table 5. Sociodemographic and clinical characteristics of study participants a 
 Total n=834 
Men 
n=610 (73.1%) 
Women 
n=224 (26.9%) p 
Median (IQR) or n (%) 
Sociodemographic characteristics  
Age (years) 48 (35, 60) 51 (37, 64) 40 (30, 53) <0.01 b 
Education (completed level/class)     
Illiterate 404 (48.4%) 272 (44.6%) 132 (58.9%) 0.03 c 
Primary e 209 (25.1%) 183 (30.0%) 26 (11.6%)  
Secondary, middle   152 (18.2%) 103 (16.9%) 49 (21.9%)  
Graduate, diploma, post-graduate 69 (8.3%) 52 (8.5%) 17 (7.6%)  
Monthly household income (INR)     
< 5000 f 354 (54.0%) 231 (50.7%) 123 (61.5%) 0.01 c 
Self-reported current cigarette 
smoking 41 (4.9%) 41 (6.7%) 0 (0.0%) --- 
d 
Clinical characteristics 
ATBD g 88 (24.2%) 80 (27.7%) 8 (10.8%) <0.01 c 
Coughing h 693 (85.9%) 516 (87.9%) 177 (80.5%) <0.01 c 
With sputum production h, i 511 (74.2%) 394 (77.0%) 117 (66.1%) <0.01 c 
With blood h, i 72 (10.5%) 59 (11.6%) 13 (7.4%) 0.10 c 
Fever 331 (41.2%) 246 (42.1%) 85 (39.0%) 0.43 c 
Night sweats 127 (15.7%) 91 (15.5%) 36 (16.4%) 0.76 c 
a Among study participants with available hemoglobin, age, and sex data (n=834). Covariates with missing observations 
included: monthly household income (n=178), cigarette smoking (n=2), HbA1c (n=598), ATBD (n=471), coughing (n=27), 
sputum production with cough (n=145), blood with cough (n=151), fever (n=31), night sweats (n=26). 
b Hodges Lehmann estimator (two-sided normal approximation based on Wilcoxon sign rank test).  
c Likelihood ratio test 
d Sample cell size < 5 
e Including completed and some primary education 
f Cut-off value of 5000 INR rounded from the cut-off of 4860 INR, which is based on monthly consumption expenditure for 
a family of five residing in a rural area (2011-12 prices), per the India national poverty line (Government of India, Planning 
Commission, 2014 Report) (12) 
g Based on AFB sputum smear microscopy. 
h According to self-report 
i Among those with cough 
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Table 6. Selected biochemical indicators of study participants a 
 Total n=834 
Men 
n=610 (73.1%) 
Women 
n=224 (26.9%) p 
b 
Median (IQR) or n (%) 
25(OH)D (nmol/L) 51.5 (36.6, 69.6) 53.5 (40.0, 74.2) 49.2 (31.7, 64.2) 0.09 i 
<25 nmol/L c 13 (9.6%) 8 (9.1%) 5 (10.4%)  0.80 j 
< 40 nmol/L d 41 (30.2%) 22 (25.0%) 19 (39.6%) 0.08 j 
<50 nmol/L d, e 64 (47.1%) 39 (44.3%) 25 (52.1%) 0.39 j 
<75 nmol/L e 110 (80.9%) 67 (76.1%) 43 (89.6%) <0.05 j 
Hemoglobin (g/L) f 115.0 (99.0, 129.7) 
120.0 (103.0, 
132.7) 102.0 (90.0, 115.0) <0.01
 i 
Anemia g 600 (71.9%) 416 (68.2%) 184 (82.1%) <0.01 j 
Severe anemia g 53 (6.4%) 32 (5.3%) 21 (9.4%) 0.04 j 
Hypochromic 
microcytic anemia 
g, h 
175 (23.0%) 108 (19.2%) 67 (34.2%) <0.01 j 
HbA1c (%) 5.4 (5.0, 5.8) 5.4 (5.1, 5.8) 5.3 (4.9, 5.7) 0.07 i 
³ 6.5% 29 (12.3%) 21 (13.0%) 8 (10.7%) 0.20 j 
< 6.5% and ³ 5.7% 48 (20.3%) 36 (22.4%) 12 (16.0%)  
< 5.7% 159 (67.4%) 104 (64.6%) 55 (73.3%)  
ESR (mm/hr) 30 (15, 55) 30 (12, 60) 25 (15, 45) 0.31 i 
Elevated ESR g 492 (59.0%) 375 (61.5%) 117 (52.2%) 0.02 j 
White blood cell 
count (cells/cmm) 
9,500 (7,740, 
12,300) 
9,700 (7,900, 
12,380) 
9,200 (7,300, 
12,100) 0.03
 i 
Elevated WBC 
(>11,000) 274 (34.4%) 213 (36.4%) 61 (28.9%) <0.05
 j 
Differential count 
(%)     
Neutrophils 68.0 (60.0, 76.0) 70.0 (61.0, 77.0) 64.0 (57.0, 72.5) <0.01 i 
Lymphocytes 23 (16, 31) 22 (15, 30) 27.5 (20.0, 34.0) <0.01 i 
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Monocytes 4 (3, 5) 4 (3, 5) 4 (3, 5) 0.73 i 
Eosinophils 4 (3, 5) 4 (3, 5) 4 (3, 5) 0.56 i 
a Among study participants with available anemia (hemoglobin) data (n=834). Covariates with missing observations 
included: 25(OH)D (n=698), hypochromic microcytic anemia (n=74), white blood cell count (n=38), lymphocytes 
(n=1). 
b Comparison by sex 
c Scientific Advisory Council of Nutrition cut-off value recommended to prevent rickets 
d Institute of Medicine cut-off values for 25(OH)D deficiency and insufficiency among healthy populations 
e Endocrine Society cut-off values for 25(OH)D deficiency and insufficiency among populations at risk of vitamin D 
deficiency 
f Hemoglobin adjusted for smoking, based on WHO recommendations. 0.3 g/L hemoglobin was subtracted among any 
individuals who self-reported as currently smoking (19). 
g See definitions in Supplementary Table 1 
h Among those with anemia 
i Hodges Lehmann estimator (two-sided normal approximation based on Wilcoxon sign rank test). Normality 
assumptions not met based on Shapiro-Wilk test statistic. 
j Likelihood ratio test 
 
 
Anthropometric indicators 
Based on the standard WHO criteria for BMI, 46.8% of men and 40.2% of women were 
considered underweight (BMI < 18.5 kg/m2; Table 7). However, only 9.0% of men and 
19.6% of women were considered overweight or obese (BMI ≥ 25.0; Table 7). 
Considering alternative WHO BMI cut-offs recommended for Asian populations (23), 
83.1% of men and 69.2% of women were underweight or normal weight (BMI < 23.0 
kg/m2; Table 7). Median WC was 70.3 cm (IQR 65.0, 80.1) among men; and 66.9 cm 
(IQR 60.7, 77.5) among women (p<0.01; Table 7). Overall, 79.3% of study participants 
were below the IDF WC cut-off (men 74.8%, women 91.9%; p<0.01; Table 7).  
 
Correlates of anemia and severe anemia 
In multivariate regressions analyses, ATBD (adjusted odds ratio [aOR] 2.51 [95% 
confidence interval [CI]: 1.01, 6.25]), elevated ESR (aOR 3.51 [95% CI: 2.48, 4.97]), 
and BMI (aOR 0.92 [95% CI: 0.88, 0.95]) were significantly associated with anemia 
(all p<0.05), adjusting for age and sex (Table 8).  
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Table 7. Anthropometric indicators among men and women a 
 Total n=834 
Men 
n=610 (73.1%) 
Women 
n=224 (26.9%) p 
b 
Median (IQR) or n (%) 
BMI (kg/m2) 18.8 (16.8, 22.2) 18.6 (16.8, 21.5) 19.6 (16.9, 23.8) <0.01
 c 
     WHO standard categories     
<18.5 357 (45.0%) 271 (46.8%) 86 (40.2%) < 0.01 d 
≥ 18.5 to < 25.0 342 (43.1%) 256 (44.2%) 86 (40.2%)  
≥ 25.0 to < 30.0 72 (9.1%) 45 (7.8%) 27 (12.6%)  
≥ 30.0  22 (2.8%) 7 (1.2%) 15 (7.0%)  
     WHO alternative 
categories     
<18.5 357 (45.0%) 271 (46.8%) 86 (40.2%) < 0.01 d 
≥ 18.5 to < 23.0 272 (34.3%) 210 (36.3%) 62 (29.0%)  
≥ 23.0 to < 27.5 121 (15.3%) 82 (14.2%) 39 (18.2%)  
≥ 27.5  43 (5.4%) 16 (2.8%) 27 (12.6%)  
WC (cm) 69.5 (63.4, 
79.6) 70.3 (65.0, 80.1) 66.9 (60.7, 77.5) 
<0.01 c 
< IDF cut-off e 634 (79.3%) 442 (74.8%) 192 (91.9%) < 0.01 d 
MUAC (cm) 23.7 (21.5, 
26.4) 23.6 (21.5, 26.2) 24.0 (21.5, 27.0) 
0.24 c 
Low MUAC (<22.0 cm 
women, <23.0 cm men) f 306 (38.2%) 246 (41.7%) 60 (28.4%) 
<0.01 d 
Low MUAC (<19.0 cm 
women, <20.0 cm men) f, g 103 (12.9%) 86 (14.6%) 17 (8.1%) 
0.01 d 
Triceps skinfold thickness 
(mm) 
9.3 (5.3, 
15.3) 13.3 (8.3, 20.0) 12.0 (7.0, 18.5) 
<0.01 c 
Total body fat (kg) 18.3 (12.7, 
25.0) 15.7 (11.0, 21.0) 28.0 (22.2, 35.1) 
<0.01 c 
Trunk fat (kg) 18.4 (11.6, 
25.4) 16.0 (10.3, 22.7) 26.0 (18.7, 35.1) 
<0.01 c 
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a Among study participants with available anemia (hemoglobin) data (n=834). Covariates with missing 
observations included: BMI (n=41), WC (n=34), MUAC (n=33), skinfold thickness (n=91), total body fat (n=41), 
trunk fat (n=41). 
b Comparison between men and women 
c Kruskal Wallis test. Normality assumptions not met based on Shapiro-Wilk test statistic. 
d Likelihood ratio test 
e International Diabetes Federation WC cut-off values among South Asian populations (men <80 cm, women <90 
cm) 
f MUAC cut-off values from previously suggested values (76) 
g Severe wasting, grade 4 malnutrition cut-off values (10) 
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Table 8. Biochemical, clinical, and sociodemographic correlates of anemia a 
 
 
Univariate regressions Multivariate regression  b 
n=793 
n OR 95% CI aOR 95% CI 
 
ATBD c 834     
Yes  4.23 1.77, 10.14 2.51 1.01, 6.25 
No  --- --- --- --- 
Not assessed  0.59 0.42, 0.82 0.51 0.35, 0.74 
Elevated ESR a 834 3.70 2.69, 5.07 3.51 2.48, 4.97 
BMI (kg/m2) 793 0.91 0.88, 0.95 0.92 0.88, 0.95 
 
Age (years) 834 1.00 0.99, 1.01 1.01 1.00, 1.02 
Sex  834     
Female  --- --- --- --- 
Male  0.47 0.32, 0.68 0.27 0.18, 0.42 
Highest educational attainment 834     
Illiterate (versus any formal 
education) 
 1.59 1.17, 2.16   
Any formal education 
(primary, secondary, graduate, 
diploma, post-graduate) 
 
--- ---   
Monthly household income 
(INR) d 
656     
< 5000  1.62 1.15, 2.27   
³ 5000  --- ---   
a See definitions in Table 11 
b Based on complete-case analysis 
c Based on AFB sputum smear microscopy 
d Cut-off value of 5000 INR rounded from the cut-off of 4860 INR, which is based on monthly consumption expenditure 
for a family of five residing in a rural area (2011-12 prices), per the India national poverty line (Government of India, 
Planning Commission, 2014 Report) (12) 
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Hemoglobin concentrations were significantly lower (102.0 g/L [IQR 88.0, 116.0]) in 
individuals with ATBD, compared to those without ATBD (114.0 g/L [IQR 100.0, 
128.0]) or individuals who were not assessed for ATBD (118.0 g/L [IQR 100.0, 132.0]; 
p<0.01). Median hematocrit also differed across ATBD status (ATBD, no ATBD, no 
ATBD assessment; p<0.01). 
 
Predictive performance of anthropometric indicators for elevated HbA1c 
Sensitivity, specificity, PPV and NPV of anthropometric indicators (BMI [standard and 
alternative WHO categorizations], and WC [IDF cut-offs]) of HbA1c ≥ 6.5% are 
presented in Table 9. Considering BMI (standard WHO categories) as an indicator for 
HbA1c ≥ 6.5%, the AUC was 0.58 among all study participants (p=0.25), sensitivity 
was 0.21 (95% CI: 0.06, 0.35), and specificity was 0.92 (95% CI: 0.88, 0.96; Table 9).  
 
We also considered the predictive performance of anthropometric indicators for 
elevated HbA1c, using a cut-off of ≥ 5.7% as the outcome of interest (Table 10). BMI 
(standard WHO categories) had similar AUCs (overall 0.49 [p=0.77], men 0.54 
[p=0.44], women 0.57 [p=0.42]), relative to diabetes as the outcome (HbA1c ≥ 6.5%). 
The AUC for WC were 0.57 (p=0.10) among all study participants, 0.53 (p=0.56) 
among men, and 0.61 (p=0.19) among women. 
 
Associations between elevated HbA1c and anthropometry 
WC (aRR 1.03 [95% CI 1.01, 1.06]; continuous variable) was associated with HbA1c ≥ 
6.5%, adjusting for age and sex. Similarly, individuals in the highest tertile of WC were  
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Table 9. Comparison of anthropometric (BMI, WC) screening cut-offs for HbA1c ³ 6.5% a, b 
  
HbA1c        
BMI c (kg/m2)                           
³6.5% <6.5%   Sensitivity (95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
 
≥ 25.0 6 
 
16 22       
< 25.0 23 178 201  0.21 
(0.06, 0.35) 
0.92 
(0.88, 0.96) 
0.27 
(0.09, 0.46) 
0.89 
(0.84, 0.93) 
 
 29 
 
194 223       
          
           
≥ 23.0 9 
 
29 38       
< 23.0 20 165 185  0.31 
(0.14, 0.48) 
0.85 
(0.80, 0.90) 
0.24 
(0.10, 0.37) 
0.89 
(0.85, 0.94) 
 
 29 
 
194 223       
          
WC  d (cm)          
                         ≥ IDF cut-off 14 
 
33 47       
                         < IDF cut-off   14 168 182  0.50 
(0.31, 0.69) 
0.84 
(0.78, 0.89) 
0.30 
(0.17, 0.43) 
0.92 
(0.88, 0.96) 
 
 28 
 
201 229       
          
a Among study participants with available data (hemoglobin, HbA1c, as well as either BMI [categorical; n=223] or WC [n=229]). 
b American Diabetes Association cut-points of HbA1c ³ 6.5%.  
c WHO classifications (standard and alternative categorization for Asian populations) 
d IDF WC cut-off values among South Asian populations (men <80 cm, women <90 cm) 
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Table 10. Comparison of anthropometric (BMI, WC) screening cut-offs for HbA1c ³ 5.7% a, b 
  
HbA1c        
BMI c (kg/m2)                           
³5.7% <5.7%   Sensitivity (95% CI) 
Specificity 
(95% CI) 
PPV 
(95% CI) 
NPV 
(95% CI) 
 
≥ 25.0 10 
 
12 22       
< 25.0 64 137 201  0.14 
(0.06, 0.21) 
0.92 
(0.88, 0.96) 
0.45 
(0.25, 0.66) 
0.68 
(0.62, 0.75) 
 
 74 
 
149 223       
          
           
≥ 23.0 16 
 
22 38       
< 23.0 58 127 185  0.22 
(0.12, 0.31) 
0.85 
(0.80, 0.91) 
0.42 
(0.26, 0.58) 
0.69  
(0.62, 0.75) 
 
 74 
 
149 223       
          
WC d (cm)          
                         ≥ IDF cut-off 23 
 
24 47       
                         < IDF cut-off   52 130 182  0.31 
(0.20, 0.41) 
0.84 
(0.79, 0.90) 
0.49 
(0.35, 0.63) 
0.71 
(0.65, 0.78) 
 
 75 
 
154 229       
          
a Among study participants with available data (hemoglobin, HbA1c, as well as either BMI [n=223] or WC [n=229]). 
b American Diabetes Association cut-points of HbA1c ³ 5.7%.  
c WHO classifications (standard and alternative categorization for Asian populations) 
d IDF WC cut-off values among South Asian populations (men <80 cm, women <90 cm) 
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positively associated with HbA1c ≥ 6.5% (Tertile 3 vs 1: adjusted risk ratio [aRR] 2.87 
[95% CI 1.19, 6.92]), compared to those in the lowest WC tertile, adjusting for age and 
sex.  
 
DISCUSSION 
In summary, we conducted a “phase 0” nutritional assessment among a clinical source 
population from which we will recruit study participants for a RCT. Our results 
indicated a high prevalence of malnutrition, based on suboptimal biochemical 
(25[OH]D, hemoglobin) as well as anthropometric indicators (BMI, WC). More than 
80% of study participants had 25(OH)D < 75 nmol/L; over 70% had anemia, including 
most men (68.2%) and women (82.1%). Among those with anemia, only 29.2% had 
hypochromia and microcytosis, which suggests that the etiology of anemia is 
multifactorial and cannot be largely attributed to iron deficiency in this population. 
Separately, anemia was associated with ATBD, adjusting for covariates. Common cut-
off values for anthropometric screening indicators had suboptimal predictive 
performance in detecting elevated HbA1c among an adult outpatient population with 
lower adiposity. Findings suggest the need for population-specific cut-offs for BMI and 
WC, given that each remained respectively associated with HbA1c. 
 
Malnutrition remains widely prevalent 
We found that 30-80% of this source population had low vitamin D (based on cut-off 
values of <40, <50, or <75 nmol/L). These estimates were higher than a prior global 
estimate, which suggested approximately one billion people had deficient or insufficient 
 59 
vitamin D (28), although the consistent use of standard reference materials and assay 
standardization is necessary for improved global estimates. In conjunction with the 
limited availability of vitamin D rich foods (natural, fortified) at the study site location, 
the high prevalence of low vitamin D suggests the potential to benefit the source 
population, in the context of a RCT of vitamin D supplementation. 
 
Based on the WHO classification, the public health significance of anemia in our source 
population (82.1% women; 68.2% men) is considered severe (19). Anemia is estimated 
to affect 1.6 billion individuals globally (29). Over 20 million women of reproductive 
age have severe anemia, which is associated with increased mortality and adverse health 
outcomes, including poor cognitive function and lowered work productivity (30). In the 
second global nutrition target, the World Health Assembly established a goal of 
reducing anemia by 50% among women of reproductive age by 2025 (4, 5).  
 
A previous global estimate of anemia prevalence is 24.8% (29), which is less than half 
the proportion observed in our source population. Moreover, in contrast to the global 
estimate of anemia among women  (29.4% (95% CI: 24.5, 35.0) (30), four of every five 
females had anemia in our study. The global mean hemoglobin among non-pregnant 
women (126.0 g/L [95% credibility interval 124.0-128.0]; 15-49 years) (31) was higher 
than the median (102.0 g/L) among women in our source population. In South Asia, the 
mean hemoglobin among non-pregnant women was 119.0 g/L (95% credibility interval 
115.0-124.0) (31), which was higher than our findings. Additionally, one study in India 
found similarly high prevalence of anemia among pregnant women (84.9%) and 
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adolescent girls (90.1%) (32).  
 
Multifactorial etiology of anemia, including tuberculosis 
Iron deficiency has been estimated to account for approximately 50% of anemia globally 
(30, 33); this is reflected in global recommendations that target iron deficiency as a 
strategy to improve iron deficiency anemia (34, 35). However, in our source population, 
70.8% of study participants with anemia did not hypochromia and microcytosis, which 
are commonly considered hematological indicators of iron deficiency anemia (20). 
Previous studies have also corroborated the substantial heterogeneity and multifactorial 
etiology of anemia across diverse populations (30, 36). Aside from iron deficiency (30, 
33), numerous other causes of anemia include: genetic hemoglobin disorders, other 
nutritional deficiencies (e.g. vitamin B12), and infectious and inflammatory diseases 
(30, 37-39). Critically, the effective prevention and management of anemia at the 
population level requires further delineation of the distribution, specific causes, and risk 
factors of anemia in diverse populations (40). 
 
Additionally, our finding of the association between anemia and ATBD was consistent 
with a previous study in Tanzania, which showed a 4-fold increased risk of ATBD 
recurrence associated with anemia without iron deficiency (p<0.001) (39). Among adult 
patients with ATBD in South Korea, 31.9% had anemia (41).  
 
Population-specific BMI and WC cut-off values for diabetes screening  
Globally, nearly one of every ten (8.5%) adults has diabetes (42), which is similar to the 
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prevalence of diabetes (12.0%) among our study participants. Worldwide, the number 
of people with diabetes has more than tripled in the past four decades (42); and is 
projected to increase to 552 million by 2030 (43). Low- and middle-income countries 
have disproportionate deaths caused by high blood glucose and diabetes currently, and 
incident diabetes cases in future estimates (42, 43). 
 
Higher BMI (overweight and obesity) and WC are well-established modifiable risk 
factors of type 2 diabetes mellitus (T2DM) (15, 24, 42, 44, 45). International and 
national public health entities (including the WHO (23, 42, 46, 47) and IDF (24)) 
recommend common cut-off values of elevated BMI and WC that identify individuals 
at risk for T2DM. 
 
However consistent with our findings, a growing body of evidence suggests research 
gaps and limitations in the predictive performance of commonly used anthropometric 
indicator cut-offs for T2DM screening. First, the heterogeneity of body fat distribution 
is hypothesized to affect T2DM risk (48), which could cause common cut-points of 
anthropometric screening indicators for diabetes to perform worse (more false negatives 
or positives) in some populations. Central and android (upper body) obesity as well as 
visceral fat (49) have been more strongly associated with insulin resistance and T2DM, 
relative to overall obesity (50, 51). Studies have demonstrated that individuals with 
similar BMI sometimes differ substantially in body fat distribution and percentage (52-
55), metabolic syndrome (56), T2DM (57, 58) and insulin resistance (59). As an 
example, the predisposition for central fat accumulation among Asian populations has 
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been observed to differ from Caucasians (60), which could explain differential T2DM 
risk among individuals with the same BMI (23). 
 
Second, studies have begun elucidating the biological basis for these observed patterns. 
At the cellular level, functional metabolic differences between adipocytes (brown, 
white, and beige [brown in white]) have been characterized (61-63). Critically, studies 
have shown metabolically active brown adipocytes associated with improved T2DM 
indicators and lower BMI (62, 64); in contrast, white adipocytes were associated with 
visceral fat, which has been linked to insulin resistance (65).  
 
Successfully addressing the diabetes epidemic requires considering effective screening 
among populations with different body composition patterns. Overall in our study, 
common cut-off values for anthropometric screening indicators had suboptimal 
predictive performance in detecting diabetes among an adult outpatient population with 
lower adiposity. Findings suggest the need for population-specific cut-offs for BMI and 
WC, given that: 1) each remained respectively associated with diabetes status; and 2) 
standard cut-offs misclassify the diabetes and pre-diabetes status of a number of study 
participants. 
  
Similar to our results, the respective associations between BMI and WC with elevated 
HbA1c have been confirmed in several studies among populations in the US and Europe 
(45, 66, 67), India (68, 69) and China (70). These studies included a US study among 
Mexican Americans, which found an 11 times greater risk of non-insulin dependent 
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diabetes mellitus among those in the highest quartile of WC, compared to the lowest 
quartile (66). Separately, previous studies have also shown a wide heterogeneity of 
predictive performance of anthropometric indicators in diabetes and pre-diabetes 
screening. As an example, one US study among 12,814 adults (45-64 years; African 
American and white), areas under the ROC curves were similar for BMI (African 
American men 0.69, White men 0.70; African American women 0.66, White women 
0.72) and WC (African American men 0.70, White men 0.70; African American women 
0.69, White women 0.73) in predicting diabetes (71). 
 
Although our results reveal several research gaps, the importance and challenges of 
determining appropriate population-specific cut-off values of anthropometric indicators 
have been acknowledged in previous literature (72-74) and by the WHO (23, 54). Future 
research questions include: What are the appropriate cut-offs across racial and ethnic 
subgroups, based on representative samples with external validity? How do different fat 
distributions (including differing body fat percentage and adipocyte type) affect the risk 
of T2DM incidence and severity? What are the cellular mechanisms involving different 
adipocyte types that contribute to T2DM development and progression? 
 
In our study, there were several strengths, including the: sample size, assessment of 
multiple BMI and WC categories (based on widely used cut-off values and population 
distribution [quantiles]), use of a 25(OH)D assay instrument that was participating in 
DEQAS, serological indicators to define microcytosis and hypochromia, and 
hemoglobin adjustment for smoking (19). 
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This study had several limitations. These included the cross-sectional study design (with 
a single timepoint assessment, which precludes etiological inference); potential residual 
confounding; external validity (generalizability of findings, especially among healthy 
populations); assessment of additional causes of low hemoglobin; biological samples 
obtained per standard of care (only from participants with a clinical indication and not 
collected at random or from all participants); and limited biomarker data, such as 
diagnostics of human immunodeficiency virus (HIV) and other clinical morbidities. 
Despite this, according to the National Acquired Immunodeficiency Syndrome Control 
Organisation (Government of India), the HIV prevalence was 0.66% among adults (15-
49 years) in Andhra Pradesh and Telangana (75).  
 
In conclusion, our results highlight the importance of nutritional profiling among 
underlying source populations, as preparation for RCTs. Among a clinical population 
in rural South India, we found: 1) a high prevalence of adverse nutritional indicators 
(suboptimal vitamin D, anemia, and underweight); 2) the co-occurrence of malnutrition, 
infectious diseases and chronic ailments (including associations between: anemia and 
ATBD, diabetes and anthropometry); and 3) the need for improved population-specific 
screening for diabetes and pre-diabetes. Effective malnutrition prevention, treatment, 
and research efforts require comprehensive nutritional assessments, in order to inform 
study designs and intervention strategies in target populations.
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Table 11. Supplemental - Definitions of anemia and related red blood cell indices 
 Hematological 
indicator 
Age Male Female Ref 
Anemia  Hemoglobin  
(g/L) b, c 
³ 18 years 
 
Non-
pregnant <130 <120 
(19)   
Pregnant 
c 
--- <110 
Severe anemia Hemoglobin  
(g/L) a, b ³ 18 years 
   
Non-
pregnant <80 <80 
(19) 
Pregnant 
c --- <70 
Red blood 
cell size 
Microcytic 
 
MCV 
(femtoliters/cel
l) 
--- <80 
(20)  Normocytic  --- ³ 80 and £ 100 
 Macrocytic 
 --- >100 
Erythrocyte 
color 
(hemoglobin 
content) 
Hypochromic MCH 
(picograms/cell
) --- 
<27 
(20) Normochromic ³ 27 and £ 33 
Hyperchromic >33 
Inflammation ESR (mm/hr) <50 years >15 >20 
(21, 
22) ³50 years and <85 >20 >30 
³85 years >30 >42 
a Data collection site is <1000 meters above sea level, and therefore there were no hemoglobin adjustments for altitude (19). 
Among current smokers, 0.3 g/L was subtracted from hemoglobin. 
b Biologically unlikely hemoglobin values (<25, >200 g/L) considered missing 
c No study participants self-reported as pregnant 
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Table 12. Supplemental - STROBE checklist for cross-sectional studies 1 
 Item 
No Recommendation 
Page 
number(s) 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 37 
(b) Provide in the abstract an informative and balanced summary of what was done and 
what was found 
37-38 
Introduction  
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 39-40 
Objectives 3 State specific objectives, including any pre-specified hypotheses 39-40 
Methods  
Study design 4 Present key elements of study design early in the paper 40-41 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, 
exposure, follow-up, and data collection 
40-47 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of selection of participants 40-47 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect 
modifiers. Give diagnostic criteria, if applicable 
40-47 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment 
(measurement). Describe comparability of assessment methods if there is more than one 
group 
40-47 
Bias 9 Describe any efforts to address potential sources of bias 58-64 
Study size 10 Explain how the study size was arrived at 40-41 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If applicable, describe 
which groupings were chosen and why 
40-47 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 40-47 
(b) Describe any methods used to examine subgroups and interactions 40-47 
(c) Explain how missing data were addressed 40-47 
(d) If applicable, describe analytical methods taking account of sampling strategy N/A 
(e) Describe any sensitivity analyses 40-47 
Results  
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Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, 
examined for eligibility, confirmed eligible, included in the study, completing follow-up, 
and analyzed 
41-42 
(b) Give reasons for non-participation at each stage 42 
(c) Consider use of a flow diagram 42 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and 
information on exposures and potential confounders 
47-53 
(b) Indicate number of participants with missing data for each variable of interest 47-53 
Outcome data 15* Report numbers of outcome events or summary measures 47-58 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their 
precision (eg, 95% confidence interval). Make clear which confounders were adjusted for 
and why they were included 
47-58 
(b) Report category boundaries when continuous variables were categorized 47-58 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a 
meaningful time period 
N/A 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity 
analyses 
47-58 
Discussion  
Key results 18 Summarize key results with reference to study objectives 58-64 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or 
imprecision. Discuss both direction and magnitude of any potential bias 
58-64 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, 
multiplicity of analyses, results from similar studies, and other relevant evidence 
58-64 
Generalizability 21 Discuss the generalizability (external validity) of the study results 58-64 
Other information  
Funding 22 Give the source of funding and the role of the funders for the present study and, if 
applicable, for the original study on which the present article is based 
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1 Available at: http://strobe-statement.org/. Accessed February 10, 2016. 
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Abbreviations 
1,25(OH)2D: 1,25-dihydroxyvitamin D  
25(OH)D: 25-hydroxyvitamin D 
AFB: acid-fast bacilli 
aRR: adjusted risk ratio 
BMI: body mass index 
DBP: vitamin D binding protein  
HbA1c: glycated hemoglobin 
IDF: International Diabetes Federation 
INR: Indian rupees 
RR: risk ratio 
TB: tuberculosis 
US: United States 
VDR: vitamin D receptor 
WC: waist circumference 
WHO: World Health Organization 
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ABSTRACT 
 
Background: Vitamin D is a potential modifiable risk factor for metabolic 
abnormalities, however this association remains unclear among populations with 
heterogeneous body distributions. Our objective was to evaluate associations between 
25-hydroxyvitamin D (25[OH]D) and metabolic risk factors (glycated hemoglobin 
[HbA1c], waist circumference [WC], blood pressure) among a population with a high 
prevalence of low body mass index (BMI). 
Methods: In this cross-sectional study, adult outpatients (n=156) in India provided 
blood samples, which were assayed for serum 25(OH)D and HbA1c. Anthropometry 
and blood pressure were measured. 
Results: Median 25(OH)D was 51.8 nmol/L (IQR 36.0, 70.0). Forty-four percent of 
participants had BMI <18.5 kg/m2; median WC was 72.8 cm (IQR 66.0, 82.0) among 
men and 67.0 cm (IQR 60.0, 76.0) among women. 31.5% of patients had HbA1c ≥ 5.7%. 
Individuals in the lowest 25(OH)D quintile had an increased risk of HbA1c ≥ 5.7% (aRR 
1.61; 95% CI: 1.02, 2.56), compared to other quintiles. 25(OH)D was inversely 
associated with WC (p<0.01), although not hypertension (p>0.05). 
Conclusion: Elevated HbA1c ≥ 5.7% and WC were associated with low 25(OH)D. 
These findings indicate the need to elucidate further mechanisms and roles of vitamin 
D in preventing and managing metabolic risk factors among populations with low BMI. 
 
Key words: Vitamin D, metabolism, glycated hemoglobin, waist circumference
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INTRODUCTION 
Metabolic risk factors affect 20-25% of adults globally and increase the risk for Type 2 
diabetes mellitus and cardiovascular disease [1-3]. In 2015, metabolic risk factors 
(including high body mass index [BMI] and fasting plasma glucose) contributed the 
most to disability-adjusted-life-years worldwide [4]. The global mean fasting plasma 
glucose has risen over the past four decades [5]. Successfully countering the burden of 
disease from metabolic abnormalities requires more effective prevention, early 
diagnosis and treatment [2]. Current mitigation efforts are substantially hindered by a 
limited understanding of the pathophysiology and etiology, as well as modifiable risk 
factors (e.g. vitamin D) of metabolic abnormalities. 
 
One major challenge has been understanding metabolic risk factors among populations 
with heterogeneous body composition. First, do metabolic processes (including 
physiological and genetic differences) differ among people with low BMI? Although 
high BMI (overweight, obese) is considered a risk factor for metabolic disorders [1], 
metabolic abnormalities are also commonly observed among some populations with low 
and normal BMI [6-10]. The prevalence of metabolic risk factors and abnormalities 
have increased in the past few decades among Asian countries (including India) [11,12], 
which have lower mean BMI than other countries in Europe and North America [13]. 
Globally, more than 60% of people with diabetes reside in Asia; approximate half of 
these individuals live in India and China [14]. 
 
There are several hypothesized explanations of the differential metabolic risk among 
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those with low BMI, including: 1) physiological (adipose tissue and cell type 
distribution [15-17], total body fat percentage [18]); and 2) genetic differences [19,20]. 
Subsequently, if metabolic processes differ among people with heterogeneous body 
composition, are there differences in clinical recommendations (including prevention, 
detection, and treatment of metabolic risk factors) and modifiable risk factors (e.g. 
vitamin D) against metabolic risk factors and disorders? 
 
Vitamin D is a potential host-directed adjuvant for metabolic risk factors because it 
affects energy homeostasis (including glycemic control, central adiposity, lipid 
metabolism) and blood pressure [21-24]. At the cellular level, 1,25-dihydroxyvitamin 
D (1,25[OH]2D) regulates adipocyte metabolism [25,26], including inhibiting 
adipogenesis [27-29]. From genetic studies, vitamin D receptor (VDR) and binding 
protein (DBP) have been associated with adipocyte metabolism, glucose tolerance, and 
insulin secretion [26,30]. Animal models have corroborated that 1,25(OH)2D inhibits 
renin gene expression, which regulates blood pressure [22]. Despite the evidence of 
links between vitamin D and metabolic risk factors, there are major research gaps in 
understanding this association, including among individuals with heterogeneous body 
compositions. 
 
Therefore, our study objective was to assess the associations between serum 25-
hydroxyvitamin D (25[OH]D) and metabolic indicators (glycated hemoglobin [HbA1c], 
waist circumference [WC], blood pressure) among an adult patient population with a 
high prevalence of low BMI. The secondary objective was to assess the association 
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between 25(OH)D and active tuberculosis (TB) disease, given the high prevalence of 
patients with suspected or confirmed active TB disease at the data collection site. 
 
MATERIALS AND METHODS 
Ethical conduct of research  
The Cornell University Institutional Review Board, and Arogyavaram Medical Centre 
Institutional Ethics Committee approved of this study. Study participants provided 
informed consent to participate. 
 
Study population 
The study design has been previously detailed. Briefly, this cross-sectional study 
recruited and enrolled study participants (n=156) during their clinical visits between 
September 2014 and May 2016. The study site was in a rural region of Andhra Pradesh, 
India at a rural hospital. This hospital has inpatient and outpatient facilities, which 
regularly provide services for patients with suspected or confirmed active TB disease. 
Hospital physicians referred outpatients to study staff. Exclusion criteria included: age 
<18 years; unavailable data for key covariates (serum 25[OH]D, total body fat, BMI); 
and declining to participate or an incomplete visit for any other reason (e.g. severe 
illness or complications). 
 
Data collection 
Trained research assistants collected sociodemographic and clinical information from 
study participants through structured interviews. A study physician conducted a 
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complete examination, including blood pressure measurements. Anthropometric 
measurements were assessed, based on World Health Organization (WHO) and other 
common recommendations [31,32]. Height and WC were measured to the nearest 0.1 
centimeter (cm); weight was assessed to the nearest 0.1 kilogram (kg). Total body and 
trunk fat (kg) were assessed by bioelectrical impedance analysis (BC-418 MA; Tanita 
Corporation, Tokyo, Japan; 8 electrode).  
 
Subgroups of study participants provided blood and sputum samples, based on clinical 
assessments by their hospital physicians and standard of care. Hospital phlebotomists 
collected blood samples, per the standard of care procedures. For active TB disease 
assessment, patients were requested to provide one sputum samples at the time of his or 
her initial hospital visit, and a second sputum sample the subsequent morning. 
 
Laboratory assays 
Serum 25(OH)D (nmol/L) was assayed by chemiluminescence immunoassay 
(LIAISON; DiaSorin Inc., Stillwater, Minnesota, United States [US]). We also 
participated in the D External Quality Assurance Scheme (DEQAS; www.deqas.org) 
program; our results were within +/- 20% of the National Institute of Standards and 
Technologies (NIST) target values. Blood samples were assayed for HbA1c (%) by 
high-performance liquid chromatography (D-10; Bio-Rad Laboratories, Hercules, 
California, US). Each sputum sample was assessed for active TB disease by the 
detection of standard acid-fast bacilli (AFB) with Ziehl-Neelsen staining and 
conventional light microscopy. Additionally, complete blood counts were assessed by 
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an automated hematology analyzer (BC-2800; Mindray Bio-Medical Electronics Co., 
Ltd., Shenzhen, People’s Republic of China).  
 
Outcomes 
WC was considered as continuous and categorical variables (International Diabetes 
Federation [IDF] cutoffs, tertiles). The IDF cutoffs were the sex-specific values (males 
<90 cm, females <80 cm), which are recommended for individuals in South Asia [33]. 
Biologically unlikely values were considered missing. HbA1c was categorized by 
common cut-off values: ≥ 6.5%, ≥ 5.7% to < 6.5%, <5.7% [34,35]. High systolic blood 
pressure was considered ≥ 140 mm Hg; and high diastolic blood pressure was ≥ 90 mm 
Hg. Additionally, we categorized individuals as having abnormal blood pressure if: 
systolic blood pressure ≥ 140 mm Hg, diastolic blood pressure ≥ 90 mm Hg, or both 
were elevated. 
 
Active TB disease status was defined as at least one positive AFB sputum smear result. 
This included patients with one positive AFB result (regardless of first or second sputum 
sample), as well as two positive AFB results, according to the standard active TB disease 
diagnostic guidelines in India [36]. 
 
Exposure 
Vitamin D status was defined with several cut-off values (25[OH]D <25.0 nmol/L [37], 
<40.0 nmol/L [38], <50.0 nmol/L [38,39], <75.0 nmol/L [39]). Additionally, we 
categorized 25(OH)D (nmol/L) by quintiles.  
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Covariates 
Sociodemographic and clinical characteristics 
Low monthly household income was considered < 5000 Indian rupees (INR). This cut-
off value was rounded up from 4860 INR, which is based on the estimated monthly 
consumption expenditures for a family of five residing in a rural area (2011-2012 prices) 
and national poverty line (Government of India, Planning Commission, 2014 Report) 
[40]. Self-reported educational attainment was categorized as illiterate, primary (grades 
1-5), secondary or middle (grades 6-12), and higher (including graduate, diploma, post-
graduate). We defined anemia and severe anemia by the WHO recommendations for 
hemoglobin cut-off values [41]. Among individuals who currently smoked, per self-
report, 0.3 g/L was subtracted from the measured hemoglobin concentration [41].  
 
Anthropometry and body composition 
Biologically unlikely values were considered missing. BMI was categorized per 
standard WHO cut-offs (underweight < 18.5 kg/m2; normal weight ≥ 18.5 and < 25.0 
kg/m2; overweight ≥ 25.0 and < 30.0 kg/m2; and obese ≥ 30.0 kg/m2) [32]. We included 
additional BMI categorizations, based on a WHO expert consultation regarding BMI 
cutpoints for Asian populations (≥ 18.5 to < 23.0 kg/m2; ≥ 23.0 to < 27.5 kg/m2; ≥ 27.5 
kg/m2) [10]. We defined limb fat as the sum of body fat (kg) of all four limbs. 
 
Statistical analysis 
Normality was assessed with the Shapiro Wilk test statistic. For descriptive statistics, 
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we reported medians and interquartile ranges (IQRs) for continuous variables, and n (%) 
for categorical variables. Differences between subgroups were compared by Wilcoxon 
sign rank or likelihood ratio tests. 
 
Per the study objectives, we assessed associations with multivariate linear and binomial 
regressions. For each outcome of interest, the selection of potential confounders was 
based on approaches suggested by Rothman and Greenland [42]. In brief, we identified 
known or suspected risk factors based on a priori literature review [22,43]. For each 
association of interest, we included the confounders in the final adjusted model based 
on a 10% change-in-estimate criterion [42]. For example, considering the association 
between vitamin D and WC, this set of covariates (including age, sex, active TB disease, 
anemia, monthly household income) were then adjusted for in each final model. For 
binary outcomes, binomial regressions were utilized when models converged. Modified 
Poisson estimates were utilized if binomial models failed to converge [44]. 
 
SAS statistical software (version 9.4; SAS Institute Incorporated, Cary, North Carolina, 
US) was utilized for all analyses. Statistical significance was assessed by two-tailed 
tests and an alpha value of 0.05. Descriptive statistics were reported in Table 13. In 
multivariate regressions, analytical subgroups were based on complete case analysis for 
each association (vitamin D and respectively, WC [n=150; Table 14], HbA1c [n=149; 
Table 15], blood pressure [n=99; Table 16], and active TB disease [n=81; Table 17]); 
the missing-data indicator method was utilized for covariates with missingness [42]. 
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RESULTS 
25-hydroxyvitamin D 
Median serum 25(OH)D was 51.8 nmol/L (IQR 36.0, 70.0; Table 13). Median 25(OH)D 
concentration was 24.9 nmol/L (IQR 19.1, 28.7), 38.8 nmol/L (IQR 35.4, 42.3), 51.7 
nmol/L (IQR 49.0, 55.2), 67.5 nmol/L (IQR 63.1, 70.0), and 82.9 nmol/L (IQR 76.9, 
102.1) in quintiles 1 through 5.  
 
Metabolic risk factors 
Among all study participants, median HbA1c was 5.3% (IQR 5.0, 5.8; Table 13). 17 
(11.4%) patients had HbA1c ≥ 6.5%, and 30 (20.1%) had HbA1c ≥ 5.7%. Median WC 
was 70.0 cm (IQR 63.0, 80.2); this differed across BMI category (p<0.01). Overall, 
median systolic blood pressure was 110 mmHg (IQR 100, 120); 11.1% of study 
participants had systolic blood pressure ≥ 140 mmHg. Median diastolic blood pressure 
was 70 mmHg (IQR 60, 80); 13.1% of patients had elevated diastolic blood pressure (≥ 
90 mmHg). 8.1% of patients had abnormal blood pressure (either elevated systolic, 
diastolic, or both). 
 
Active tuberculosis disease and other study participant characteristics 
Among patients assessed for active TB disease (n=81), 19 (23.5%) had a positive AFB 
sputum smear microscopy result (Table 13).  
 
In terms of sociodemographic characteristics, the median age was 45.0 years (IQR 30.0, 
60.0). The majority of the study population was male (n=100 [64.1%]). 39.1% of study 
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Table 13. Sociodemographic and clinical characteristics, stratified by BMI, 
among patients in rural South India a,b 
  BMI  
  Under 
weight 
Normal 
weight 
Over 
weight 
Obese p c 
 N=156 (<18.5) (≥ 18.5 to 
< 23.0) 
(≥ 23.0 to 
< 27.5) 
(≥ 27.5)  
  64 
(43.8%) 
59 
(40.4%) 
16 
(11.0%) 
7 (4.8%)  
Sociodemographic       
Age (years) 
45.0 (30.0, 
60.0) 
44.0 
(29.5, 
60.0) 
40.0 
(29.0, 
53.0) 
53.5 (44.5, 
62.5) 
40.0 
(19.0, 
50.0) 
0.10 d 
Sex (male) 
100 
(64.1%) 
42 
(65.6%) 
38 
(64.4%) 
9 (56.3%) 2 (28.6%) 0.27 e 
Education (completed 
level/class) 
     0.04 e 
Illiterate 
61 
(39.1%) 
26 
(40.6%) 
17 
(28.8%) 
11 
(68.8%) 
3 (42.9%)  
Primary f 
40 
(25.6%) 
17 
(26.6%) 
18 
(30.5%) 
2 (12.5%) 0 (0.0%)  
Secondary, middle   
35 
(22.4%) 
15 
(23.4%) 
13 
(22.0%) 
3 (18.8%) 3 (42.9%)  
Graduate, diploma, post-
graduate 
20 
(12.8%) 
6 (9.4%) 11 
(18.6%) 
0 (0.0%) 1 (14.3%)  
Monthly household 
income (INR) 
      
< 5000 g 
60 
(47.2%) 
29 
(53.7%) 
21 
(42.9%) 
6 (60.0%) 2 (28.6%) 0.41 e 
 Clinical       
25(OH)D (nmol/L) 
51.8 (36.0, 
70.0) 
53.5 
(37.9, 
75.9) 
51.7 
(35.3, 
70.3) 
47.4 (29.1, 
56.6) 
35.4 
(16.2, 
39.4) 
0.05 d 
<25 i 
17 
(10.9%) 
7 (10.9%) 6 (10.2%) 2 (12.5%) 2 (28.6%) 0.65 e 
< 40 j 
49 
(31.4%) 
19 
(29.7%) 
18 
(30.5%) 
6 (37.5%) 6 (85.7%) 0.03 e 
<50  j,k 
73 
(46.8%) 
29 
(45.3%) 
27 
(45.8%) 
9 (56.3%) 6 (85.7%) 0.17 e 
<75 k 
126 
(80.8%) 
47 
(73.4%) 
48 
(81.4%) 
16 
(100.0%) 
7 
(100.0%) 
<0.01 e 
Waist circumference 
(cm) 
70.0 (63.0, 
80.2) 
63.1 
(59.0, 
67.5) 
75.0 
(70.0, 
81.5) 
91.0 (83.0, 
95.3) 
87.0 
(84.0, 
103.2) 
<0.01 d 
Body composition       
Total body fat (%) 
18.1 (12.2, 
24.0) 
12.2 (7.8, 
17.7) 
20.7 
(15.7, 
27.9) 
28.3 (23.1, 
37.3) 
40.0 
(32.1, 
43.1) 
<0.01 d 
Trunk fat (kg) 
4.3 (2.2, 
7.3) 
2.2 (1.3, 
3.7) 
6.0 (4.1, 
8.0) 
10.0 (8.4, 
12.5) 
17.2 
(13.2, 
17.7) 
<0.01 d 
Limb fat (kg) l 3.9 (2.6, 2.6 (1.6, 4.3 (3.7, 7.1 (5.9, 11.5 (9.8, <0.01 d 
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5.6) 3.4) 5.7) 8.9) 12.4) 
Fat free mass (kg) 
38.1 (33.1, 
43.2) 
35.7 
(30.9, 
39.1) 
41.2 
(34.1, 
44.3) 
43.2 (34.4, 
51.7) 
41.9 
(39.1, 
58.8) 
<0.01 d 
HbA1c (%) 
5.3 (5.0, 
5.8) 
5.3 (5.0, 
5.7) 
5.4 (5.0, 
5.9) 
5.5 (5.1, 
6.1) 
5.7 (4.5, 
6.3) 
0.55 d 
≥ 6.5 
17 
(11.4%) 
5 (8.2%) 8 (14.3%) 3 (20.0%) 1 (14.3%) 0.59  e 
< 6.5 and ≥ 5.7 
30 
(20.1%) 
11 
(18.0%) 
11 
(19.6%) 
2 (13.3%) 3 (42.9%)  
< 5.7 
102 
(68.5%) 
45 
(73.8%) 
37 
(66.1%) 
10 
(66.7%) 
3 (42.9%)  
Active TB disease m 
19 
(23.5%) 
10 
(23.3%) 
6 (27.3%) 1 (16.7%) 2 (14.3%) 0.70 e 
Hemoglobin (g/dL) 
107.0 
(96.5, 
125.0) 
100.0 
(90.0, 
118.0) 
115.5 
(100.0, 
130.0) 
113.0 
(101.0, 
120.9) 
115.0 
(110.0, 
117.0) 
0.04  d 
Anemia 
105 
(77.2%) 
49 
(87.5%) 
33 
(66.0%) 
12 
(75.0%) 
5 (83.3%) 0.06 e 
Severe anemia 11 (8.1%) 6 (10.7%) 3 (6.0%) 0 (0.0%) 0 (0.0%) 0.23 e 
Blood Pressure n       
Systolic (mmHg; 
continuous) 
110 (100, 
120) 
110 (100, 
120) 
110 (110, 
120) 
120 (110, 
130) 
120 (110, 
130) 
0.09 d 
Systolic ≥ 140 mmHg 
11 
(11.1%) 
4 (8.9%) 4 (12.9%) 2 (18.2%) 1 (20.0%) 0.78 e 
Diastolic (mmHg; 
continuous) 
70 (60, 
80) 
70 (60, 
80) 
70 (70, 
80) 
70 (70, 
90) 
80 (80, 
80) 
0.36 d 
Diastolic ≥ 90 mmHg 
13 
(13.1%) 
4 (8.9%) 5 (16.1%) 3 (27.3%) 1 (20.0%) 0.45 e 
Abnormal blood 
pressure 
8 (8.1%) 2 (4.4%) 3 (9.7%) 2 (18.2%) 1 (20.0%) 0.42 e 
Footnotes 
a Abbreviations: body mass index (BMI), glycated hemoglobin (HbA1c), Indian rupees (INR), interquartile range (IQR), 
tuberculosis (TB) 
b Among study participants with available 25(OH)D data (n=156). Covariates with missing observations included: monthly 
household income (n=183), BMI (n=10), waist circumference (n=6), total body fat (n=10), trunk fat (n=10), limb fat (n=10), 
HbA1c (n=7), active tuberculosis disease (n=75), hemoglobin (n=20), systolic or diastolic blood pressure (n=57). 
c Comparison by BMI categories 
d Wilcoxon sign rank test. Normality assumptions not met based on Shapiro-Wilk test statistic. 
e Likelihood ratio test 
f Including completed and some primary education 
g Cut-off value of 5000 INR rounded from the cut-off of 4860 INR, which is based on monthly consumption expenditure for a 
family of five residing in a rural area (2011-12 prices), and the India national poverty line (Government of India, Planning 
Commission, 2014 Report) (10) 
h Any current self-reported tobacco use, including cigarettes, chewing tobacco, pan, gutkha, bidi 
i Scientific Advisory Council of Nutrition cut-off value recommended to prevent rickets 
j Institute of Medicine cut-off values for 25(OH)D deficiency and insufficiency among healthy populations 
k Endocrine Society cut-off values for 25(OH)D deficiency and insufficiency among populations at risk of vitamin D 
deficiency 
l Sum of body fat (kg) in four limbs (arms, legs) 
m Based on acid-fast bacilli sputum smear microscopy 
n Elevated blood pressure cut-off values from the National Institutes of Health (NHLBI): 
https://www.nhlbi.nih.gov/health/health-topics/topics/hbp 
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participants were illiterate (n=61); and similarly, approximately half had a monthly 
household income < 5000 INR (n=60 [47.2%]). 
 
Approximately half of study participants (n=64 [43.8%]) were considered underweight 
(BMI < 18.5 kg/m2; Table 13); nearly one-fifth were either overweight (23.0 kg/m2 ≤ 
BMI < 27.5 kg/m2; 11.0%) or obese (BMI ≥ 27.5 kg/m2; 4.8%). Median values of body 
composition indicators included: total body fat 18.1% (IQR 12.2, 24.0), trunk fat 4.3 kg 
(IQR 2.2, 7.3), limb fat 3.9 kg (IQR, 2.6, 5.6), and fat free mass 38.1 kg (IQR 33.1, 
43.2). All body composition indicators differed across BMI categories (all p<0.01). 
 
Association between 25(OH)D and metabolic risk factors 
Serum 25(OH)D (nmol/L) was associated with WC (cm; p<0.05), adjusting for age, sex, 
active TB disease, and tobacco use (Table 14). Similarly, 25(OH)D < 50 nmol/L was 
associated with WC (cm; p=0.05), adjusting for the same covariates (Table 14). 
However in contrast, 25(OH)D was not associated with elevated WC (above the IDF 
cut-off values) in other multivariate linear and binomial (or Poisson) regression models 
(p>0.05; Table 14). 
 
Vitamin D (25[OH]D) < 50 nmol/L was associated with HbA1c (%; p=0.04), adjusting 
for age and fat free mass (Table 15). The lowest quintile of serum 25(OH)D was 
associated with an increased risk of HbA1c ≥ 5.7% (adjusted risk ratio [aRR] 1.61 [95% 
CI 1.02, 2.56]) compared to the other quintiles, adjusting for age and trunk fat (Table 
15). However, the other associations that were assessed between 25(OH)D (continuous, 
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Table 14. Serum 25-hydroxyvitamin D and waist circumference (n=150) 
Vitamin D  
(25[OH]D) 
Waist circumference (continuous [cm]; linear 
regression) 
Waist circumference (categorical; binomial 
regression) a, c 
Unadjusted Adjusted b Unadjusted Adjusted b 
β (SE) p β (SE) p RR 95% CI aRR 95% CI 
Continuous (nmol/L) -0.08 (0.04) 0.03 -0.10 (0.04) <0.01 1.00 d 1.00, 1.01 1.00 d 1.00, 1.01 
< 50 nmol/L (Endocrine Society) 3.15 (1.93) 0.10 3.63 (1.84) 0.05 0.85 0.72, 1.01 0.82 d 0.56, 1.19 
Quintiles (low 1 vs 2-5) 0.24 (2.53) 0.92 0.24 (2.45) 0.92 0.98 0.78, 1.22 0.95 d 0.58, 1.54 
Footnotes 
a High vs low WC. Cut-offs based on IDF WC cutoffs among South Asian populations. 
b We considered known or suspected risk factors for waist circumference as potential confounders. These potential confounders were included if p<0.25 from univariate regressions (linear or 
binomial regression model beta coefficients; likelihood ratio tests). Based on a change in estimate approach, covariates were included in the final adjusted model if they changed the estimate by 
≥10%. The final covariates for the association of waist circumference (categorical) and vitamin D (quintiles 1 vs 2-5) were utilized in final models in this table; these included: age, sex, active TB 
disease, anemia, monthly household income. 
c Binomial regression unless otherwise stated 
d Poisson regression due to no model convergence 
<50 nmol/L) were not associated with HbA1c (continuous, ≥ 6.5% or ≥ 5.7%; p>0.05; Table 15). For example, 25(OH)D (nmol/L) 
was not associated with HbA1c (%; p=0.27), adjusting for covariates. 
 
The considered associations between 25(OH)D (continuous, <50 nmol/L) were not associated with blood pressure, including systolic 
(continuous, elevated), diastolic (continuous, elevated), and abnormally high blood pressure (p>0.05; Table 16). 
 
Association between 25(OH)D and active tuberculosis disease 
The lowest quintile of 25(OH)D was not associated with active TB disease (aRR 1.93 [95% CI 0.53, 7.08]), accounting for age, sex, 
anemia, total body fat, and limb fat (Table 17).  
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Table 15. Serum 25-hydroxyvitamin D and glycated hemoglobin (n=149) 
Vitamin D  
(25[OH]D) 
HbA1c (continuous; linear 
Regression) 
HbA1c (categorical ≥ 6.5%; binomial 
regression) a, c 
HbA1c (categorical ≥ 5.7%; binomial 
regression) a, c 
Unadjusted Adjusted b Unadjusted Adjusted b Unadjusted Adjusted b 
β (SE) p β (SE) p RR 95% CI RR 95% CI RR 95% CI RR 95% CI 
Continuous 
(nmol/L) 
<-0.01 
(<0.01) 0.48 
<-0.01 
(<0.01) 0.27 1.00 0.98, 1.01 0.99 
d 0.97, 1.01 0.99 0.98, 1.01 0.99 0.98, 1.00 
< 50 nmol/L 
(Endocrine 
Society) 
0.40 
(0.27) 0.13 
0.54 
(0.27) 0.04 1.57 0.63, 3.90 1.80 
d 0.67, 4.84 1.36 0.84, 2.19 1.54 0.98, 2.41 
Quintiles (low 1 vs 
2-5) 
0.09 
(0.33) 0.79 
0.21 
(0.33) 0.52 0.82 0.25, 2.66 0.92 
d 0.26, 3.34 1.46 0.88, 2.40 1.61 1.02, 2.56 
Footnotes 
a HbA1c cut-offs based on WHO and IDF recommendations 
b We considered known or suspected risk factors for HbA1c as potential confounders. These potential confounders were included if p<0.25 from univariate regressions (linear or binomial 
regression model beta coefficients; likelihood ratio tests). Based on a change in estimate approach, covariates were included in the final adjusted model if they changed the estimate by ≥10%. 
The final covariates for the association of HbA1c (categorical, >=5.7%) and vitamin D (quintiles 1 vs 2-5) were utilized in final models in this table; these included: age, trunk fat.     
c Binomial regression unless otherwise stated 
d Poisson regression due to no model convergence	
 
 
DISCUSSION 
In summary, our findings showed associations between vitamin D (25[OH]D) and HbA1c (≥ 5.7%), as well as WC among an adult 
outpatient population in rural India. Neither blood pressure nor active TB disease was associated with serum 25(OH)D concentrations. 
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Table 16. Serum 25-hydroxyvitamin D and blood pressure (n= 99) 
Vitamin D  
(25[OH]D) 
Systolic 
(continuous; 
linear regression) 
b 
Elevated systolic 
(categorical ≥140 
mmHg; binomial 
regression) a, b, c  
Diastolic 
(continuous; linear 
regression) b 
Elevated diastolic 
(categorical ≥90 
mmHg; binomial 
regression) a, b, c 
Abnormal (categorical 
either systolic ≥140 
mmHg or diastolic ≥90 
mmHg; Poisson 
regression) a, b, c 
Adjusted 
β (SE) p RR 95% CI β (SE) p RR 95% CI RR 95% CI 
Continuous (nmol/L) -0.07 (0.07) 0.35 0.97 d 0.94, 1.01 -0.04 (0.05) 0.48 1.00 d 0.97, 1.03 0.97 d 0.92, 1.02 
< 50 nmol/L (Endocrine 
Society) 
5.45 (3.28) 0.10 4.00 d 0.96, 16.56 3.49 (2.41) 0.15 0.93 d 0.27, 3.22 4.07 d 0.62, 26.60 
Quintiles (low 1 vs 2-5) 0.19 (4.61) 0.97 1.14 d 0.18, 7.17 -0.19 (3.37) 0.96 0.55 d 0.08, 3.66 2.55 d 0.19, 33.45 
Footnotes 
a Elevated blood pressure cut-off values from the National Institutes of Health (NHLBI): https://www.nhlbi.nih.gov/health/health-topics/topics/hbp 
b We considered known or suspected risk factors for blood pressure as potential confounders. These potential confounders were included if p<0.25 from univariate regressions (linear or binomial 
regression model beta coefficients; likelihood ratio tests). Based on a change in estimate approach, covariates were included in the final adjusted model if they changed the estimate by ≥10%. 
The final covariates for the associations between hypertension (elevated systolic, diastolic, or both) and vitamin D (quintiles 1 vs 2-5) were utilized in final models in this table; these included: 
age, active TB disease, body fat, limb fat, trunk fat, fat free mass, illiterate, household income.    
c Binomial regression unless otherwise stated 
d Poisson regression due to no model convergence 
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Table 17. Serum 25-hydroxyvitamin D and active TB disease (n=81) 
Vitamin D  
(25[OH]D) 
Active TB disease (categorical; binomial regression) a, c 
Unadjusted Adjusted b 
RR 95% CI RR 95% CI 
Continuous (nmol/L) 0.99 0.98, 1.01 0.99 d 0.97, 1.01 
< 50 nmol/L (Endocrine Society) 0.91 0.41, 2.02 0.98 d 0.38, 2.52 
Quintiles (low 1 vs 2-5) 1.39 0.55, 3.53 1.93 d 0.53, 7.08 
Footnotes 
a Active TB disease assessed by AFB sputum smear microscopy 
b We considered known or suspected risk factors for active TB disease as potential confounders. These potential 
confounders were included if p<0.25 from univariate regressions (linear or binomial regression model beta coefficients; 
likelihood ratio tests). Based on a change in estimate approach, covariates were included in the final adjusted model if 
they changed the estimate by ≥10%. The final covariates for the association of active TB disease (categorical) and 
vitamin D (quintiles 1 vs 2-5) were utilized in final models in this table; these included: age, sex, anemia, body fat, limb 
fat, household income. 
c Binomial regression unless otherwise stated 
d Poisson regression due to no model convergence 
 
Vitamin D as a modifiable risk factor of metabolic indicators 
Previous systematic reviews have found associations between vitamin D 
supplementation and HbA1c [45,46], which is consistent with our result. In a systematic 
review of vitamin D (or vitamin D analogues) supplementation during pre-diabetes, 
vitamin D supplementation was associated with a mean HbA1c difference of -1 
mmol/mol (95% CI -2, 0; p=0.008) [45]. Another systematic review found vitamin D 
supplementation (versus placebo) was associated HbA1c (mean difference -0.13%; 
p=0.04) [46]. Other systematic reviews have observed null results [47-49], however 
intervention studies have included inconsistent methodology, including vitamin D 
dosage (duration, frequency, dosage). 
 
Our finding that serum 25(OH)D was inversely associated with WC, which has been 
corroborated by other studies focusing on visceral adiposity [22]. At the cellular level, 
other key findings have supported epidemiological findings, including the: a) isolation 
of VDR as well as hydroxylating enzymes of vitamin D in adipose tissues; and b) 
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storage and release of vitamin D in adipocytes [25-29,50]. Many questions remain, in 
order to elucidate the etiology and mechanisms of 25(OH)D in the context of adiposity 
and energy homeostasis [21], including: How does VDR signaling occur in adipocytes, 
particularly during abnormal metabolism? How does the vitamin D 
activation:inactivation ratio in adipocytes differ during metabolic dysfunction as well 
as in different types of adipose tissue and cells? Are there other lipid-mediated 
regulatory processes that affect or interact with vitamin D metabolism in adipocytes 
(e.g. PPAR-gamma)? 
 
Despite our result of a null association between low 25(OH)D and high systolic blood 
pressure, prior literature has supported an inverse association between 25(OH)D and the 
renin-angiotensin-aldosterone-system (RAAS), which regulates hypertension [51-53]. 
One hypothesized mechanism is that elevated vitamin D inhibits renin gene expression, 
which dampens the RAAS activity and subsequently decreases blood pressure [52-55]. 
One study corroborated that cardiac renin mRNA expression increased in VDR 
knockout mice [56]. In a randomized controlled trial among patients with arterial 
hypertension and 25(OH)D <30 ng/mL at baseline, vitamin D3 supplementation (2800 
IU) resulted in an increased mean difference of plasma aldosterone concentration 
(p=0.04), relative to placebo [55]. Additionally, a systematic review of vitamin D 
supplementation randomized controlled trials found that vitamin D supplements were 
associated with lowered blood pressure in two of nine meta-analyses [57]. 
 
Vitamin D in active tuberculosis disease 
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Other studies have found evidence of the link between vitamin D and the human host 
defense against Mycobacterium tuberculosis [58,59], in contrast to our finding. One 
systematic review showed lower vitamin D status among patients with active TB 
disease, compared to controls; and vitamin D deficiency was associated with an 
increased risk of incident active TB disease among those with latent TB infection [60]. 
Other clinical studies have also found null results, however additional longitudinal 
studies are needed, particularly in order to account for active TB disease severity, anti-
TB treatment (e.g. duration, drug combinations [1st versus 2nd line], adherence), and 
other comorbidities (e.g. HIV). 
 
Strengths and limitations 
In this study, strengths included: the assessment of several metabolic risk factors, and a 
study population with a high prevalence of low BMI, which allowed for consideration 
of these associations among individuals with heterogeneous body composition.  
 
However, there were several limitations. First, causal inferences were precluded by the 
cross-sectional study design. Second, findings cannot be generalized to other 
populations, given the small sample size and non-random selection of study participants 
who provided blood samples. Third, lipid data were not available. Low high-density 
lipoprotein cholesterol (men <40 mg/dL, women <50 mg/dL) and elevated triglycerides 
(≥ 150 mg/dL) are considered one criteria in the definition of metabolic syndrome [2]. 
Additionally, BIA was utilized for body composition assessments instead of other 
methods (e.g. dual-energy x-ray absorptiometry or underwater weighing) [61,62]; and 
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there was no clinical diagnoses data of diabetes.  
 
Conclusion 
Our results corroborated the associations of low vitamin D with both elevated HbA1c 
and WC among a population with a high prevalence of low BMI. While further 
mechanistic and longitudinal studies are needed to better understand the roles of vitamin 
D, these findings support the potential role of vitamin D as a modifiable risk factor in 
preventing and managing metabolic risk factors in populations with low BMI.  
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ABSTRACT 
Background 
Globally, active tuberculosis is the ninth leading cause of death. Prior studies indicate 
that inflammation has a dual role in mediating both the pathogenesis of and the human 
host immune response against Mycobacterium tuberculosis. Therefore, understanding 
key human host factors (including vitamin D, the gut microbiome) with bi-directional 
effects on inflammation is important in mitigating tuberculosis (TB) transmission and 
the burden from active TB disease. As an initial step towards understanding these 
complex associations, we investigated the gut microbiome composition among patients 
with ATBD at ATT initiation and assessed its association with vitamin D status in a 
rural setting in India.  
 
Methods 
In this cross-sectional study, outpatients (n=32) with ATBD (Xpert MTB/RIF-
confirmed) were enrolled at initiation of ATT at a hospital. Rectal swab samples were 
assayed by 16S rRNA sequencing (Illumina MiSeq; V3-V4 hypervariable regions). 
Serum 25-hydroxyvitamin D (25[OH]D) concentrations were assessed by liquid 
chromatography mass spectrometry and categorized by cut-off values (<25, <40, <50, 
<75 nmol/L) and quintiles. 
 
Results 
Median serum 25(OH)D concentration was 46.0 nmol/L (IQR 36.1, 60.7). Overall, the 
majority of identified sequences were from four phyla: Firmicutes (median 46.1% [IQR 
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36.5, 51.6]), Bacteroidetes (32.4% [24.5, 40.4]), Proteobacteria (9.3% [6.1, 55.3]), and 
Actinobacteria (2.1% [1.3, 4.2]). The median Firmicutes:Bacteroidetes ratio was 1.3 
(IQR 1.0, 1.8). Mean alpha diversity indices were: Shannon (5.1 [SD 1.1]), and Chao1 
(1023.6 [350.5]); the median Simpson index was 0.9 (IQR 0.9, 1.0). Alpha diversity 
indices did not differ by vitamin D status (cut-off values and quintiles; all p>0.05). 
 
Conclusions 
Among this population of adult outpatients with ATBD, the relative abundance of 
identified operational taxonomic units were predominantly in the Bacteroidetes and 
Firmicutes phyla, which is consistent with previous literature among healthy 
populations. Further longitudinal and mechanistic studies are needed to assess the roles 
of vitamin D and the human microbiome in the context of inflammation and ATBD, 
particularly in resource-limited environments.  
 
Keywords 
Microbiome, vitamin D, micronutrients, tuberculosis 
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INTRODUCTION 
Globally, active tuberculosis (TB) disease (ATBD) is the ninth leading cause of death, 
and caused 53 million deaths from 2000 to 2016 [1]. Inflammation mediates the success 
of the human host versus Mycobacterium tuberculosis [2, 3], and is regulated by both 
the human host and M. tuberculosis [2]. In the human host, an adequate pro-
inflammatory response prevents ATBD, however subsequent balance is required to 
avoid deleterious consequences [4]. As part of its survival mechanism, M. tuberculosis 
interferes with the inflammatory response, in order to restrict host immunity and support 
caseating necrotic granulomas [2, 3]. Therefore, our goal was to elucidate human host 
factors (including vitamin D, gut microbiome) that have bi-directional effects on the 
tightly regulated inflammatory response during ATBD. 
 
Vitamin D modulates the innate and adaptive immune responses D [5-15], including 
inflammation that influences the host response to M. tuberculosis [16] and microbial 
communities [14]. Hypothesized mechanisms include: 1) T cell development and 
function (decreasing T helper [TH]1, TH2, TH17; increasing Treg); and 2) upregulating 
antimicrobial peptides (e.g. cathelicidin) [9-12, 14, 15]. 
 
Separately, there have been complex interactions observed between gut microbiome, 
inflammation, ATBD and anti-TB treatment (ATT) [17-19]. ATT causes dysbiosis of 
the human gut microbiome, which was shown in a human study (with dysbiosis lasting 
 116 
at least 1.2 years) [17], and a longitudinal murine study that assessed dysbiosis 
throughout the duration of ATT [18]. Among available studies, ATBD was associated 
with lower bacterial diversity and number of species [19]. 
 
Despite previous evidence (including hypothesized mechanisms), there is a limited 
understanding of the linkages between vitamin D and the gut microbiome during disease 
states [20-25], including ATBD [22, 23]. Therefore, our study objectives were to: 1) 
characterize the gut microbiome composition and diversity; and 2) compare differences 
between those with differing serum micronutrient concentrations of 25-hydroxyvitamin 
D (25[OH]D), among adult patients with ATBD. 
 
METHODS 
Patients 
This study protocol was approved by ethics review committees at Cornell University 
(Institutional Review Board, United States) and Arogyavaram Medical Centre (AMC; 
Institutional Ethics Committee, India). All study participants voluntarily provided 
written informed consent, prior to any data collection. This cross-sectional study 
included adult patients (n=32). Study participants were recruited and enrolled at a 
hospital (AMC) in a rural region of South India. Inclusion criteria were: any outpatient; 
ATBD based on Xpert MTB/RIF. The exclusion criteria were: age (<18 years); 
receiving ATT (>4 weeks in past 5 years); other severe illnesses or conditions requiring 
 117 
hospitalization (aside from preventative TB hospitalization); and pregnancy or lactation. 
 
Data collection 
Blood and sputum samples were collected from study participants, per standard of care. 
Rectal swabs were collected and inserted in tubes with modified Cary-Blair medium (2 
mL), according to the manufacturer instructions (Copan FecalSwabTM Regular 
Flocked Collection Kit; Thermofisher Scientific [Copan Italia], Brescia, Italy). The 
rectal swab samples were initially stored at 4ºC and subsequently at -20ºC or -80ºC until 
deoxyribonucleic acid (DNA) extraction. Trained research assistants and a study 
physician collected data regarding current and past morbidities (e.g. diarrhea, 
respiratory illness) and medications (including antibiotics), anthropometry, dietary 
recall, and sociodemographic information through structured interviews and clinical 
examinations. 
 
25-hydroxyvitamin D 
Serum samples were evaluated for 25(OH)D (ng/mL) by liquid chromatography 
tandem-mass spectrometry (LC-MS/MS; Waters AcquityTM ultra-performance liquid 
chromatography with triple quadrupole detector; Waters Corporation, Milford, 
Massachusetts, United States [US]). The coefficients of variation (CVs) for the LC-
MS/MS instrument were 7.6%, 7.4%, and 7.6% (Internal Quality Control Kit for total 
hydroxyvitamin D; Bio-Rad Laboratories, Irvine, CA, US). Results were multiplied by 
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a conversion factor of 2.496, and reported in nmol/L.  
 
Active TB disease and CRP 
Sputum samples were assayed by Xpert MTB/RIF (Cepheid, Sunnyvale, California, 
US) to evaluate ATBD status [26]. C-reactive protein (CRP) was assessed by latex 
enhanced immunoturbidimetry (mg/dL; Advia 1800 Chemistry Analyzer; Siemens 
Healthcare Diagnostics Inc., Washington, DC, US). 
 
Gut microbiome: 16S rRNA sequencing and analysis 
Overall, the workflow (DNA extraction, amplification, 16S ribosomal ribonucleic acid 
(rRNA) sequencing, and taxonomic classification) was based on the Earth Microbiome 
Project protocols [27]. 
 
DNA extraction and real-time quantitative PCR 
DNA was extracted from rectal swabs with QIAmp DNA Mini kits (Qiagen Inc., 
Valencia, CA, US), based on the manufacturer instructions. Genomic DNA 
concentration was quantified (NanoDrop spectrophotometer; NanoDrop Technologies, 
Wilmington, DE, US). 25 ng of each sample was utilized for polymerase chain reaction 
(PCR) amplification (KAPA HiFi HotStart PCR Kit; KAPA Biosystems, Boston, MA, 
US), which was optimized for V3-V4 primers (26 cycles, 0.2 µM concentrations of 
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forward and reverse primers). 
 
Library preparation 
V3 and V4 hypervariable regions in the 16S rRNA gene of bacteria were targeted by 
primers (proprietary; Genotypic Technology Pvt. Ltd.; Bangalore, Karnataka, India). 
Sequencing adaptors (Nextera XT v2 Index Kit, Illumina, San Diego, CA, US) were 
added to barcode the amplicon libraries (Table 24). PCR validation steps included: 
positive and negative control samples, and amplicon confirmation with 1.2% agarose 
gel. 
 
Sequencing and taxonomic classification 
Amplicons (16S rRNA gene, V3 and V4 regions) were sequenced by the MiSeq 
platform (Illumina, San Diego, CA, US). The initial processing of sequencing reads 
included: demultiplexing the raw paired end reads from Miseq (bcl2fastq software; 
Illumina, San Diego, CA, US), quality filtering (e.g. fragment length, primer sequence 
presence [FastQC2] [28]), and stitching from the EA-Utils NGS suite (fastq-join, 
https://expressionanalysis.github.io/ea-utils/). Reads with Phred quality score <30 were 
excluded. 
 
Taxonomic assignment of sequences was based on closed-reference operational 
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taxonomic units (OTUs) with the Quantitative Insights into Microbial Ecology platform 
(QIIME, version 1.9.0) [29]. The uclust software package (version 1.2.22) was utilized 
to compare sequences with the Greengenes reference database sequences (version 13.8) 
[30, 31]. Reads failing to match the reference database with <97% sequence identity 
were discarded, based on other protocols [27, 32]. 
 
Visualization 
R packages were utilized for data visualization, including heat maps with nonnegative 
matrix factorization (NMF; R package) [33]. Weighted and unweighted UniFrac 
distances [34] were visualized by principal coordinates analysis (PCoA). 
 
Definitions 
Prior to alpha diversity calculations, data were rarified with a depth of 100,000 reads. 
Shannon, Simpson, and Chao diversity indices were calculated through QIIME.  
 
25(OH)D (nmol/L) was categorized by several cutpoints: D <25.0 [35], <40.0 [36], 
<50.0 [36, 37] and <75.0 nmol/L [37]. Serum 25(OH)D was also categorized in tertiles 
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and quintiles. 
 
Statistical analysis 
Preliminary analysis considered assumptions for normality (by Shapiro-Wilk test 
statistic). For descriptive analysis of study participant characteristics, means (with 
standard deviations [SD]), medians (with interquartile ranges), and n [%] were reported. 
Differences between subgroups of study participants (based on outcomes and patient 
characteristics of interest) were compared by parametric (ANOVA) or non-parametric 
(Kruskal-Wallis, Fisher’s exact) tests.  
 
The associations of interest (serum 25[OH]D concentrations) were considered in linear 
regression models. Confounding was accounted for, based on the approach proposed by 
Rothman and Greenland [38] and a priori literature search of potential confounders [39]. 
Aside from microbiome analysis software (e.g. QIIME), other software included R and 
SAS (SAS Institute Inc., Cary, North Carolina, US).  
 
All statistical tests were 2-sided, and p<0.05 were considered statistically significant. 
After statistical tests, we utilized false discovery rates (FDR) per the Benjamini and 
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Hochberg approach [40], as post-hoc multiple testing corrections. 
 
RESULTS 
Sociodemographic and clinical characteristics 
Among the study population, the median age was 55.0 years (IQR 42.0, 60.0), and 
ranged between 19.0 and 70.0 years (Table 19). Over three-quarters of the study 
participants were male (78.1%; Table 19). All participants reported coughing during the 
month prior to the study visit; 60.0% had sputum in their cough (Table 19). Also, 6.7% 
had hemoptysis in the previous four weeks (Table 19). Eighty percent of study 
participants had fever and loss of appetite (Table 19). None had reported having night 
sweats (Table 19). These clinical signs did not differ by 25(OH)D status (<50 nmol/L; 
p>0.05; Table 19). 
  
Serum biomarkers 
Median serum 25(OH)D was 46.0 nmol/L (IQR 36.1, 60.7; total of D2 and D3); 
stratified across tertiles, the median values were: 27.0 nmol/L (IQR 20.6, 35.4), 45.5 
nmol/L (IQR 42.3, 49.2), and 75.8 nmol/L (IQR 60.6, 90.4; Table 20). The median 
values of 25(OH)D2 was 2.8 nmol/L (IQR 2.5, 4.1); and D3 was 42.2 nmol/L (IQR 
33.5, 58.1; Table 20). Considering several cut-off values of low vitamin D status, 81.3% 
of study participants had 25(OH)D <75 nmol/L, 62.5% were <50 nmol/L, 34.4% were 
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<40 nmol/L, and 12.5% were <25 nmol/L (Table 20). The median serum concentration 
of CRP was 7.2 mg/dL (IQR 3.6, 11.2; Table 20). CRP was inversely correlated (ß -
2.57 [SE 1.10]; p<0.05) with 25(OH)D, adjusting for age and sex. 
 
Gut microbiome 
In this clinical adult study population, the mean number of identified sequences was 
165,323.9 (SD 92,958.9). Sequences predominantly belonged to four phyla: Firmicutes 
(median 46.1% [IQR 36.5, 51.6]), Bacteroidetes (median 32.4% [IQR 24.5, 40.4]), 
Proteobacteria (median 9.3% [IQR 6.1, 55.3]), and Actinobacteria (median 2.1% [IQR 
1.3, 4.2]; Table 21). Bar plot and heat map visualizations of the relative bacterial 
abundance of OTUs at the phyla level also confirmed this observation (Figures 3A and 
4A). The median ratio between Firmicutes and Bacteroidetes was 1.3 (IQR 1.0, 1.8; 
Table 21), and ranged from 0.1 to 14.2. The Firmicutes:Bacteroidetes ratio differed 
significantly by age (p<0.05). 
 
In terms of the family level, many OTUs were categorized as Prevotellaceae, 
Ruminococcaceae, and Lachnospiraceae (Figure 3B). At the genus level, sequences 
primarily were in the following categories: Prevotella (median 11.7% [IQR 4.0, 24.3]), 
Bacteroides (median 5.0% [IQR 1.2, 14.3]), Faecalibacterium (median 4.8% [IQR 1.5,  
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Table 19. Sociodemographic and clinical characteristics of study participants 
Median (IQR) a; n (%)  25(OH)D b 
 Overall 
n=32 c 
<50 nmol/L 
n=20 
≥50 nmol/L 
n=12 p 
Age (years) 55.0 (42.0, 60.0) 52.0 (38.0, 59.0) 56.0 (55.0, 60.0) 0.21 d 
Sex (male) 25 (78.1%) 14 (70.0%) 11 (92.7%) 0.21 e 
Coughing g 15 (100.0%) 8 (100.0%) 7 (100.0%) --- f 
With sputum g 9 (60.0%) 5 (62.5%) 4 (57.1%) 1.00 e 
With blood g 1 (6.7%) 0 (0.0%) 1 (14.3%) --- f 
Fever g 12 (80.0%) 6 (75.0%) 6 (85.7%) 1.00 e 
Night sweats g 0 (0.0%) 0 (0.0%) 0 (0.0%) --- f 
Loss of appetite g 12 (80.0%) 6 (75.0%) 6 (85.7%) 1.00 e 
a Based on the Shapiro-Wilk test, the median (and IQR) values were reported since the null hypothesis was rejected 
b 25(OH)D (nmol/L) assessed by LCMS 
c Covariates with missing observations included: age (n=14), clinical signs and symptoms (n=17). 
d Comparison between subgroups by Kruskal-Wallis test statistic 
e Fisher’s exact test 
f Sample cell sizes including zero values 
g Clinical signs and symptoms were reported from the month prior to the study visit, and based on self-report 
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Table 20. Serum concentrations of vitamin D and CRP a 
Median (IQR); n (%)  
 Overall 
n=32 
25(OH)D (nmol/L)  
 Total (D2 and D3) 46.0 (36.1, 60.7) 
D2 2.8 (2.5, 4.1) 
D3 42.2 (33.5, 58.1) 
                                   Cut-off values  
<25 b 4 (12.5%) 
< 40 c 11 (34.4%) 
<50  c, d 20 (62.5%) 
<75 d 26 (81.3%) 
                                   Tertiles  
1 (low) 27.0 (20.6, 35.4) 
2 45.5 (42.3, 49.2) 
3 (high) 75.8 (60.6, 90.4) 
  
                                   Quintiles  
1 (low) 21.7 (16.9, 26.0) 
2 38.5 (35.4, 41.8) 
3 46.0 (44.7, 49.0) 
4 58.9 (54.7, 60.8) 
5 (high) 87.7 (77.7, 90.7) 
CRP (mg/dL) 7.2 (3.6, 11.2) 
                                   Tertiles  
1 (low) 1.4 (1.1, 3.5) 
2 7.1 (4.7, 7.9) 
3 (high) 12.5 (11.0, 14,1) 
a Plasma concentrations reported for two study participants had inadequate serum aliquot 
volume 
b Scientific Advisory Council of Nutrition cut-off value recommended to prevent rickets 
c Institute of Medicine cut-off values for 25(OH)D deficiency and insufficiency among 
healthy populations 
d Endocrine Society cut-off values for 25(OH)D deficiency and insufficiency among 
populations at risk of vitamin D deficiency 
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Table 21. Relative abundance of OTUs (%) at phyla level, among total and comparisons by vitamin D status a 
 Total 25(OH)D (nmol/L) 
Cut-off Tertiles Quintiles 
Median 
(IQR) b 
< 75 ≥ 75 p c < 50 ≥ 50 p c < 40 ≥ 40 p c < 25 ≥ 25 p c p c p c 
Firmicutes  46.1 (36.5, 
51.6) 
46.3 
(38.4, 
51.8) 
38.0 
(18.1, 
48.7) 
0.45 46.3 
(32.5, 
50.7) 
41.0 
(36.7, 
52.5) 
0.94 44.5 
(24.4, 
46.7) 
46.5 
(38.8, 
52.4) 
0.45 32.5 
(16.7, 
42.2) 
46.5 
(38.6, 
52.1) 
0.30 0.59 0.30 
Bacteroidetes 32.4 (24.5, 
40.4) 
32.6 
(26.2, 
40.6) 
27.3 (5.9, 
34.6) 
0.81 32.5 
(21.8, 
40.4) 
30.4 
(27.3, 
42.6) 
0.88 35.9 
(21.0, 
40.7) 
30.5 
(26.8, 
39.1) 
0.88 35.6 
(27.5, 
39.8) 
31.5 
(23.6, 
40.5) 
0.88 0.88 0.81 
Proteobacteria 9.3 (6.1, 
28.1) 
9.1 
(6.0, 
21.0) 
35.3 
(10.4, 
55.3) 
0.44 9.1 (6.1, 
24.8) 
9.9 (4.5, 
38.9) 
0.91 12.7 (2.9, 
29.9) 
9.2 (6.8, 
21.0) 
0.91 21.3 
(10.8, 
46.6) 
9.2 (5.9, 
24.3) 
0.44 0.89 0.44 
Fusobacteria 0.3 (<0.1, 
3.8) 
0.5 
(<0.1, 
5.4) 
0.1 
(<0.1, 
0.4) 
0.92 0.5 
(<0.1, 
7.5) 
0.1 (<0.1, 
0.8) 
0.92 <0.1 
(<0.1, 
6.6) 
0.3 (<0.1, 
3.4) 
0.92 3.3 (<0.1, 
7.5) 
0.3 (<0.1, 
3.1) 
0.92 0.92 0.92 
Actinobacteria 2.1 (1.3, 
4.2) 
2.4 
(1.5, 
4.4) 
1.3 (0.8, 
3.3) 
0.66 2.5 (1.4, 
4.8) 
1.7 (1.0, 
2.8) 
0.66 2.6 (1.5, 
5.3) 
1.8 (1.2, 
3.3) 
0.66 2.0 (1.2, 
6.6) 
2.1 (1.3, 
4.2) 
0.91 0.66 0.76 
Firmicutes: 
Bacteroidetes 
ratio 
1.3 (1.0, 
1.8) 
1.3 
(1.0, 
1.7) 
1.6 (0.9, 
2.7) 
0.70 1.2 (1.0, 
1.8) 
1.5 (0.9, 
2.1) 
0.70 1.2 (1.0, 
1.4) 
1.5 (1.1, 
1.9) 
0.62 0.8 (0.5, 
1.2) 
1.4 (1.1, 
2.2) 
0.30 0.70 0.62 
a Included five phyla with the highest mean relative abundance of OTUs 
b Based on the Shapiro-Wilk test, the median (and IQR) values were reported since the null hypothesis was rejected. 
c Comparison between subgroups by Kruskal-Wallis test statistic 
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6.5]), as well as several unidentified genera (Table 22; Figure 4B). 
 
Overall, mean number of OTUs was 915.8 (SD 340.0), and ranged between 381 to 1737 
among the study population (Table 23). The mean values of the following diversity 
indices were: Shannon (5.1 [SD 1.1]), Chao1 (1023.6 [SD 350.5]); the median value of 
Simpson was 0.9 (IQR 0.9, 1.0; Table 23). 
 
Gut microbiome and vitamin D 
The relative abundance of OTUs at the phyla and genus levels did not differ significantly, 
based on any of the considered subgroups based on 25(OH)D concentration (<25, <40, 
<50, <75 nmol/L; tertiles and quintiles; all p>0.05; Tables 21 and 22). The ratio of 
Firmicutes:Bacteroidetes were similar across categories of vitamin D status (p>0.05; 
Tables 21 and 22). Diversity indices (Shannon, Simpson, Chao1) also did not differ by 
vitamin D status (p>0.05; Table 23). 
 
DISCUSSION 
Among this population of adult outpatients with ATBD, the relative abundance of 
identified OTUs were predominantly in the Bacteroides and Firmicutes phyla, which is 
similar to other studies among healthy adults. 
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Phyla Family 
A                                 B 
 
  
Figure 3: Bar plots of relative bacterial abundance in the gut microbiome of adult outpatients 
Bar plots indicate the proportion of bacterial OTUs among the total number of OTUs identified in each of the samples (columns) at 
the phyla (Fig. 1A) and family levels (Fig. 1B). The identified taxa with the highest proportions were included in these plots. 
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Distance 
Figure 4: Heat map representation of the relative abundance of bacterial OTUs, stratified by vitamin D status 
Relative bacterial abundance at the A) phyla and B) genus levels, with vitamin D status indicated by purple bars (see key above). 
The identified taxa with the highest proportions were considered. The correlation distance (see color scale in key) was considered 
with NMF and row clustering. 
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Table 22. Relative abundance of OTUs (%) at genus level, among total and comparisons by vitamin D status a 
 Total 25(OH)D (nmol/L) 
Cut-off Tertiles Quintiles 
Median 
(IQR) b 
< 75 ≥ 75 p c < 50 ≥ 50 p c < 40 ≥ 40 p c < 25 ≥ 25 p c p c p c 
Prevotella 11.7 (4.0, 
24.3) 
13.8 
(6.0, 
25.0) 
6.6 
(2.2, 
22.7) 
0.95 13.3 
(5.3, 
24.3) 
11.2 (2.8, 
24.5) 
0.95 11.1 (1.7, 
26.5) 
12.2 (6.0, 
22.7) 
0.95 17.3 
(5.9, 
24.3) 
11.7 (4.0, 
24.6) 
0.95 0.95 0.95 
Bacteroides 5.0 (1.2, 
14.3) 
5.0 (1.0, 
14.0) 
4.4 
(1.9, 
14.5) 
0.92 4.5 (0.9, 
12.9) 
5.3 (2.0, 
15.7) 
0.92 4.4 (0.7, 
21.9) 
2.1 (0.9, 
5.2) 
0.92 18.0 
(9.2, 
22.2) 
4.2 (0.9, 
11.8) 
0.54 1.00 0.92 
Faecalibacterium 4.8 (1.5, 
6.5) 
4.9 (1.2, 
7.3) 
3.2 
(1.8, 
5.8) 
0.47 5.0 (1.2, 
7.4) 
3.3 (2.4, 
5.5) 
0.44 5.0 (1.2, 
7.6) 
4.4 (1.8, 
5.8) 
0.44 6.8 (3.6, 
8.1) 
4.5 (1.5, 
6.1) 
0.44 0.44 0.44 
Porphyromonas 0.4 (<0.1, 
2.2) 
0.4 
(<0.1, 
2.4) 
0.2 
(<0.1, 
0.8) 
0.91 0.4 
(<0.1, 
2.2) 
0.4 
(<0.1, 
2.2) 
0.91 0.4 
(<0.1, 
1.7) 
0.3 
(<0.1, 
2.4) 
0.91 0.5 (0.1, 
1.3) 
0.4 
(<0.1, 
2.4) 
0.91 0.91 0.91 
1-68 0.2 (<0.1, 
2.0) 
0.2 
(<0.1, 
3.1) 
0.4 
(<0.1, 
0.5) 
0.86 0.2 
(<0.1, 
2.7) 
0.4 
(<0.1, 
0.8) 
0.86 0.2 
(<0.1, 
0.3) 
0.4 
(<0.1, 
2.3) 
0.86 0.2 (0.1, 
2.1) 
0.3 
(<0.1, 
2.0) 
0.86 0.86 0.86 
WAL_1855D 0.2 (<0.1, 
1.7) 
0.2 
(<0.1, 
1.3) 
0.8 
(<0.1, 
2.8) 
0.98 0.2 
(<0.1, 
1.5) 
0.1 
(<0.1, 
2.2) 
0.98 0.2 
(<0.1, 
1.3) 
0.2 
(<0.1, 
1.8) 
0.98 0.7 (0.2, 
2.1) 
0.1 
(<0.1, 
1.7) 
0.98 0.98 0.98 
a Included five bacterial genus with the highest mean relative abundance of OTUs, and that were categorized when compared to the 
reference database 
b Based on the Shapiro-Wilk test, the median (and IQR) values were reported since the null hypothesis was rejected. 
c Comparison between subgroups by Kruskal-Wallis test statistic 
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Table 23. Diversity indices and OTUs, stratified by vitamin D status 
 Total 25(OH)D (nmol/L) 
Cut-off Tertiles Quintiles 
Mean 
(SD) a 
< 75 ≥ 75 p b < 50 ≥ 50 p b < 40 ≥ 40 p b < 25 ≥ 25 p b p b p b 
Diversity 
index 
Shannon 5.1 
(1.1) 
5.1 
(1.1) 
4.8 
(1.2) 
0.73 5.0 (1.2) 5.1 (1.0) 0.73 4.8 (1.1) 5.2 
(1.1) 
0.73 4.9 
(1.6) 
5.1 (1.1) 0.73 0.73 0.73 
Simpson 
a 
0.9 
(0.9, 
1.0) 
0.9 
(0.9, 
1.0) 
0.9 (0.8, 
1.0) 
0.86 0.9 (0.9, 
1.0) 
0.9 (0.9, 
1.0) 
1.00 0.9 (0.9, 
1.0) 
0.9 (0.9, 
1.0) 
0.86 0.9 
(0.8, 
1.0) 
0.9 (0.9, 
1.0) 
1.00 0.90 0.86 
Chao1 1023.6 
(350.5) 
1019.1 
(350.3
) 
1042.8 
(315.3) 
0.92 1000.2 
(347.3) 
1062.5 
(367.8) 
0.92 992.7 
(358.4) 
1039.7 
(354.1) 
0.92 962.0 
(364.5) 
1032.4 
(354.5) 
0.92 0.92 0.92 
OTUs 915.8 
(340.0) 
919.6 
(351.3
) 
899.2 
(315.3) 
0.90 884.0 
(346.8) 
968.8 
(336.6) 
0.90 848.7 
(356.4) 
950.9 
(334.6) 
0.90 875.8 
(456.3) 
921.5 
(330.7) 
0.90 0.90 0.90 
Species (#) 647.5 
(219.3) 
659.2 
(226.8
) 
596.8 
(192.7) 
0.97 646.5 
(223.0) 
649.3 
(222.9) 
0.97 653.7 
(229.3) 
644.2 
(219.6) 
0.97 748.5 
(182.1) 
633.1 
(223.2) 
0.97 0.97 0.97 
a Mean (SD) reported for all values except for Simpson (due to normality assumptions assessment, per Shapiro-Wilk test) 
b Comparisons between subgroups by ANOVA (parametric) or Kruskal-Wallis (non-parametric) test statistics 
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Gut microbiome composition and abundance in active TB disease 
Our findings were consistent with previous literature, which also found that the relative 
OTU abundance were predominantly in the Bacteroides and Firmicutes phyla [41-44]. 
Other studies have found higher proportions of Bacteroides and Firmicutes (> 90.0% 
[41, 44]), compared to 78.5% in our results. 
 
Other studies have noted the potential relevance of the ratio of Firmicutes:Bacteriodetes 
as a microbiota indicator associated with aging and obesity [44, 45]. Our median 
Firmicutes:Bacteroidetes ratio (1.3) was either similar [46] or much lower than other 
studies among adults (e.g. 10.9 [45]), although our population included patients with 
ATBD. Prior studies have also found that the Firmicutes:Bacteriodetes ratio is affected 
by obesity [44, 47]. Based on another study at the same medical center, our source 
population nearly all had BMI considered underweight or normal, which could account 
for the lower ratio observed. 
 
Vitamin D during active TB disease 
The median vitamin D status (46.0 nmol/L) of our study participants was within a wide 
range of 25(OH)D concentrations observed among other studies of individuals with 
ATBD [48-50]. Previous studies have observed mean or median 25(OH)D 
concentrations in plasma or serum from 9.8 nmol/L to 78.3 nmol/L among patients with 
ATBD [48-50]. 
 
The evidence from vitamin D supplementation trials among patients with ATBD on its 
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impact on TB-related treatment outcomes has been inconsistent [51-55]. Hypothesized 
explanations include that it is necessary to first determine the appropriate intervention 
(including dosage, frequency, duration) [56]. 
 
Gut microbiome and vitamin D 
While our results showed no association between vitamin D and gut microbiota, 
previous evidence has shown links between the gut microbiome and vitamin D [57]. 
Bacterial products (secondary bile acids, digested foods [e.g. butyrate, short-chain fatty 
acids]) have been shown to induce antimicrobial peptides (cathelicidin, LL-37) that 
interact with vitamin D and vitamin D receptor (VDR) [57-59]. Two murine gene 
deletion studies demonstrated that VDR and cytochrome P450 (CYP27B1) knockout 
mice had altered intestinal microbiota, including increased Bacteroidetes [60, 61]. 
Additionally, 1,25-dihydroxyvitamin D (1,25[OH]2D) treatment in CYP27B1 knockout 
mice was protective against colitis severity and decreased Helicobacteraceae in fecal 
samples [61]. 
 
In a study among 150 young adults in Brazil, the relative bacterial abundances of 
Coprococcus and Bifidobacterium were inversely correlated with 25(OH)D 
concentration [43]. In a genome-wide association study (GWAS) among 1,812 
individuals in Germany, allelic variations of the VDR gene were associated with 
differing gut microbial characteristics [62]. 
 
C-reactive protein and vitamin D 
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In our study, serum CRP was inversely associated with vitamin D, which was similar to 
other studies [63, 64]. From a systematic review and meta-analysis of vitamin D 
supplementation randomized controlled trials (RCTs), higher dosages of cholecalciferol 
(≥ 1,000 IU per day) were associated with lower CRP (p<0.05) [64]. Additionally, 
previous evidence corroborated the complex dynamics between inflammation, vitamin 
D, gut microbiome, and ATBD  [16, 63, 65]. As a general inflammatory indicator, CRP 
may function as an effect modifier (such as in modulating the association between 
vitamin D and ATBD or anti-TB treatment-related outcomes [16, 63]) or exposure (e.g. 
an indicator of inflammation which alters gut microbial communities [65]). 
 
Strengths and limitations 
To our knowledge, this is the first study to examine vitamin D and the gut microbiome 
among patients with ATBD at ATT initiation. Given the persistence of major challenges 
in addressing ATBD [1], evaluating key human host factors (including vitamin D and 
the gut microbiome) that affect inflammation may represent a means to improve ATBD 
treatment and prevent ATBD-related adverse outcomes. Additionally, there are a 
limited number of studies that have evaluated intestinal microbiome among individuals 
residing in resource-limited settings, including India. Given this context, 16S rRNA 
sequencing provided the appropriate resolution for our study objective. 
 
However, this study also had several limitations, including the small sample size, cross-
sectional study design, and laboratory assays. Further longitudinal studies with multiple 
timepoints as well as mechanistic studies (including functional analysis) are necessary, 
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in order to better understand causal relationships [66]. Additionally, 16S rRNA 
sequencing has a number of technological limitations, including short read length and 
error rates (e.g. detecting some variations) [67]. 
 
One major challenge is appropriately accounting for confounding factors that might 
affect the association between vitamin D and the gut microbiome, particularly in light 
of the relatively recent technological advances allowing for high throughput 16S rRNA 
sequencing [66-68]. Moreover, the symbiotic relationship between the gut microbiome 
and human hosts (including micronutrient status such as vitamin D) encompasses bi-
directional and complex interactions, which span from mutualistic, commensal, to 
parasitic relationships [57, 69-73]. Gastrointestinal tract microbiota are involved in the 
digestion and de novo synthesis of micronutrients [71-75]. Conversely, micronutrients 
(and related factors) have been linked to altered gut microbiota composition and 
diversity, as well as bacterial fitness [71-74, 76, 77].  
 
Broadly, there are major challenges in understanding the gut microbiome and vitamin 
D among patients with ATBD. Many stem from research regarding the intra- and inter-
individual variability of the gut microbiome in health as well as disease [78]. However, 
the Human Microbiome Project recently found microbiota variability can be accounted 
for by blood biomarkers (7.6%), clinical characteristics (5.2%), as well as diet (5.7%) 
[78]. Additionally, other microbiomes (such as airway microbiome) need to be 
considered in future studies, including prior to and during ATBD and with differing 
vitamin D status.
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Table 24. Supplemental - Illumina adapter sequences 
5’ AATGATACGGCGACCACCGAGATCTACAC [i5] TCGTCGGCAGCGTC 3’ 
5’ CAAGCAGAAGACGGCATACGAGAT [i7] GTCTCGTGGGCTCGG 3’ 
[i5, i7]: Unique dual index sequence to identify sample-specific sequencing data  
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CHAPTER V: Conclusions 
In summary, metabolic abnormalities affect a large proportion of the global population, 
and increase the risk of other morbidities (Type 2 diabetes mellitus, cardiovascular 
diseases). Active TB disease is the ninth leading cause of death globally. Some 
geographic regions have the dual burden of metabolic abnormalities and active TB 
disease, which have observed synergistic interactions at the population level. Our 
overall goal was to assess key human host factors, including vitamin D and the gut 
microbiome, which affect this dual burden and have bi-directional effects on 
inflammation.  
 
Therefore, our primary objectives were to:  
2) assess the predictive performance of common anthropometric cut-offs utilized 
in diabetes population screening;  
3) examine the association between vitamin D and metabolic indicators;  
4) assess gut microbiota differences based on serum 25-hydroxyvitamin D status;  
among a population with a high prevalence of suspected or confirmed active TB disease, 
and low or normal body mass index (BMI). Our main findings are summarized below. 
 
Population-screening (anthropometric cut-offs) for elevated HbA1c 
Our findings indicate that one-third of study participants had elevated HbA1c (≥ 5.7%), 
despite the fact that nearly nine of every ten individuals had low or normal BMI (<25 
kg/m2; Chapter II). BMI and WC were respectively associated with HbA1c (≥ 6.5%), 
however had low sensitivity for identifying those with elevated HbA1c. These results 
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suggest the need for population-specific cut-offs for BMI and WC, as screening tools 
for diabetes.  
 
Vitamin D and metabolic abnormalities 
Individuals in the lowest 25(OH)D quintile had an increased risk of HbA1c ≥ 5.7% (aRR 
1.61; 95% CI: 1.02, 2.56), compared to other quintiles. 25(OH)D was inversely 
associated with WC (p<0.01), although not hypertension (p>0.05; Chapter III).  
 
Vitamin D and the gut microbiome 
Among this population of adult outpatients with ATBD, the relative abundance of 
identified OTUs were predominantly in the Bacteroidetes and Firmicutes phyla, which 
is consistent with previous literature among healthy populations (Chapter IV). 
 
Overall, further studies are needed to elucidate the potential roles and mechanistic 
pathways of vitamin D and the gut microbiome in preventing and managing the dual 
burden of disease from metabolic abnormalities and active TB disease among 
populations with low BMI in resource-limited settings. 
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Abstract 
The human microbiome is an intriguing potentially modifiable risk factor in our arsenal 
against Mycobacterium tuberculosis, the leading infectious disease killer globally. 
Previous studies have shown associations between the human microbiome and 
pulmonary disease states, however etiological links between the microbiome and 
tuberculosis (TB) infection or disease remain unclear. Immunomodulatory roles of the 
microbiome may prove to be a critical asset in the host response against TB, including 
in preventing TB infection, reducing progression from latency, mitigating disease 
severity, and lowering the incidence of drug resistance and co-infections. 
 
This review examined the associations between TB and the gut and lung microbiome. 
Eight studies were identified through a PubMed database search, including one animal 
study (n = 1), case report (n = 1), and case-control studies (n = 6). TB infection and 
disease were associated with reduced gastrointestinal microbial diversity in a murine 
model and human case report. Sputum microbial diversity differed by TB status in case-
control studies, although some reported heterogeneous findings. Current evidence 
suggests that the gut and lung microbiome are associated with TB infection and disease. 
However as studies are limited, etiological and longitudinal research is needed to 
determine clinical relevance.  
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INTRODUCTION 
Mycobacterium tuberculosis caused 1.5 million deaths in 2014,1 and one-third of the 
global population has latent tuberculosis (TB).2 The scourge of TB infection and disease 
has been documented since early human history, and highlights the substantial 
remaining challenges of TB control and eradication efforts. In addition to current 
strategies, successfully addressing TB infection and disease may require targeting other 
modifiable risk factors, including host microbiota. 
 
The number of host cells comprising the human body is vastly outnumbered by the 
number of symbiotic microorganisms,3 and therefore interactions between host cells and 
microbes occur constantly. The microbiome refers to “the ecological community of 
commensal, symbiotic, and pathogenic microorganisms that literally share our body 
space.”4 Previous studies have highlighted potential roles of the gastrointestinal and 
lower respiratory tract’s microbiome in the immunological response against TB 
infection and disease. Generally, bi-directional linkages between the gut microbiome 
and immune system have been well-documented.5, 6 Gut microbiota have been 
associated with a number of disease states, including asthma, autoimmune disorders, 
cardiovascular diseases, non-alcoholic fatty liver disease.5, 6, 7 
 
This review assessed the association between TB infection and disease and the gut and 
lung microbiome. The microbiome may have important implications for addressing 
major challenges to effective TB control, including through immunomodulation, in 
order to reduce and address TB transmission, progression from latency, disease severity, 
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and drug resistance. 
 
Tuberculosis Pathology and Immune Response 
M. tuberculosis bacilli are transmitted from patients with active TB through airborne 
droplets.2 In lungs, the innate host response includes the detection (by Toll-like 
receptors) and elimination (via alveolar macrophages and dendritic cells inducing 
antimicrobial peptides [cathelicidin] and autophagy) of M. tuberculosis.8 Gamma-
interferon and tumor necrosis factor-alpha activate the antimycobacterial capacity of 
macrophages, through producing nitric oxide, reactive oxygen and nitrogen 
intermediates.8 Immune cells (macrophages, fibroblasts, T and B cells) accumulate to 
form granulomas, surrounding M. tuberculosis and restricting growth.8 Despite these 
host defenses, survival mechanisms of M. tuberculosis (including inhibiting 
phagolysosome fusion) allow some bacteria to persist within granulomas.8 
 
In terms of adaptive immunity, cell-mediated responses by cluster of differentiation 
(CD)4+ and CD8+ T cells are critical to successfully address M. tuberculosis.8 Primary 
effector functions of CD4+ and CD8+ T cells include: producing gamma-interferon and 
cytokines to activate macrophages, and lysing infected macrophages.8 The T helper 
(Th1) cytokine expression pattern is important to eliminate M. tuberculosis;9 conversely, 
Th2 and regulatory T (Treg) cell responses support M. tuberculosis survival.8, 10 However, 
an enhanced Th1 response simultaneously causes inflammation and host tissue 
damage,11 which suggests a balanced Th1/Th2 immune response is ideal for patient 
health outcomes. In summary, the dynamic interplay between host immune response 
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and M. tuberculosis survival mechanisms (such as T cell homeostasis) is modulated 
through numerous factors, potentially including the microbiome.  
 
The Gut and Lung Microbiome  
Gut bacteria play important roles in nutrient metabolism, intestinal homeostasis 
(through preventing overgrowth of intestinal pathogens), and immunity.5, 12, 13 Several 
studies have examined the associations between altered gut microbiota and clinical 
pathologies including inflammatory bowel disease, diabetes, and obesity.5, 6, 14  
 
Historically, the lower respiratory tract has been considered sterile in healthy 
individuals, but recent culture-independent studies have shown evidence to the 
contrary.15, 16 Given the limited available studies focusing on the lung microbiome, one 
key research gap is determining whether the observed microbiota are simply a 
continuation of the upper respiratory tract or separate. Preliminary findings corroborate 
that microbial populations present in the lung are distinct from the upper respiratory 
tract,17 and show intra-lung heterogeneity.16 
 
Immunomodulation of Microbiota  
Murine studies involving gut microbiota have provided evidence of the modulation of 
microbiota by the immune system. In one study, transgenic mice with expression of 
human defensin 5, antimicrobial polypeptides secreted by Paneth cells in the small 
intestine, received a virulent Salmonella typhimurium challenge.18 The transgenic mice 
had lower bacterial burden in their terminal ilea, compared to wild-type controls.18 
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Additionally, mice lacking specific proteins involved in innate immunity (Toll-like 
receptor 5, nucleotide-binding and oligomerization domain-like receptor pyrin domain-
containing 6) had intestinal dysbiosis and associated pathologies, including colitis or 
insulin sensitivity.19, 20 Subsequently, the transfer of altered microbiota to wild-type mice 
was observed to lead to disease.20 Based on preliminary data, hypotheses include that: 
immune responses (including against M. tuberculosis) facilitate cross-talk between 
microbial populations (e.g. between the lung and gut microbiome); and dysbiotic 
microbiota may adversely influence some clinical pathologies. 
 
Microbial diversity is hypothesized to affect the growth of particular opportunistic 
pathogens, due to resource competition. Krishna et al. (2016) observed that 
opportunistic pathogens (Rothia mucilaginosa) were associated with increased 
complexity and diversity of sputum microbiota among patients with active TB.21 Iwai 
et al. (2014) reported that lower bacterial burden was associated with increased 
community richness (taxa per sample) and phylogenetic diversity among Ugandans with 
human immunodeficiency virus and acute pneumonia.22  
 
Influence of the Microbiome on Immunity  
Conversely, specific commensal gut microorganism species have been observed to 
modulate the immune system.23, 24, 25, 26 Gut bacteria species (Bacteroides fragilis species, 
Clostridium genus) were associated with altered Treg cell counts, function, and 
development.23, 24 Previous studies have reported the influence of bacteria on respiratory 
health, including: 1) airway inflammation, and 2) lung damage (in the context of 
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influenza and probiotic supplementation). In germ-free mice, increased airway 
inflammation was rescued by the administration of certain bacterial species 
(Faecalibacterium, Lachnospira, Rothia, and Veillonella).26 Similarly, greater 
abundance of bacteria species (Veillonella, Prevotella) in the supraglottic-characteristic 
taxa were associated with higher indicators of airway inflammation.27  
 
Moreover, two studies showed links between gut bacteria and lung damage. Disrupted 
gut microbiota (decreased Bifidobacterium and Lactobacillus) was associated with 
altered immune response to influenza A infection and increased lung damage in a 
murine model.28 Separately, probiotic supplementation of Bifidobacterium was 
associated with improved Toll-like receptor 7 response and reduced lung damage.28 One 
hypothesis is that probiotics are protective against pneumococcal disease through 
modulating the upper respiratory tract microbiome.29  
 
In summary, given these dynamic bi-directional interactions between the microbiome 
and host immunity, commensal bacteria could have a role in the immunological 
response to pulmonary TB infection and disease. Specific commensal microorganisms 
may facilitate the cell-mediated immune response to TB infection and disease, and 
modulate inflammation and lung damage through functional changes of the 
metagenome and metabolite production.12, 13 
 
TUBERCULOSIS AND THE MICROBIOME 
In this review, 8 studies examined the association between pulmonary TB infection and 
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disease and the microbiome, including: an animal study,30 a case report,31 and 6 case-
control studies (Table 25).21, 32, 33, 34, 35, 36 Key study findings are highlighted in the 
following two sections (regarding TB and the gut or lung microbiome, respectively), 
and study methodology is compared in the third section.  
 
Tuberculosis and the Gut Microbiome 
 Low bacterial species richness and abundance were found in gastrointestinal 
tract samples from mice and a patient with active TB (Table 25).30, 31 Five female 
BALB/c mice were infected with aerosolized M. tuberculosis (CDC1551 strain).30 Pre- 
and post-infection samples differed, in terms of bacterial abundance (among 88 
operational taxonomic units [OTUs]; q<0.01) and composition (beta-diversity indices 
of weighted and unweighted UniFrac distances by Principal Coordinate Analysis 
[PCoA]; both p≤0.005).30 In a second experiment, mice were infected with a different 
strain of M. tuberculosis (H37Rv; n=5), and compared to 1:1 age-matched controls.30 
Fecal samples from a single time point post-infection similarly showed differential 
clustering and bacterial abundance (among 73 OTUs; q<0•01), compared to uninfected 
samples.30 In the case report, Dubourg et al. (2013) obtained stool samples from a patient 
with multi-drug resistant active TB who previously received multiple oral antibiotic 
regimens.31 Gut microbiota were severely depleted (39 bacterial species, 18 phylotypes, 
and 19 OTUs).31 
 
Other studies have corroborated the potential role of intestinal microbiota in TB. Perry 
et al. (2010) reported that individuals with latent TB and Helicobacter pylori (H. pylori)  
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Table 25. Studies assessing the association between tuberculosis and the lung and gut microbiome a 
Study Design Sample Size Location Exposure Outcome Key Findings Ref 
Assessment Biological 
Specimen 
Microbial 
Assessment 
Method(s) 
Hypervar
iable 
Regions b Cases Controls 
Murine Model 5 female 
BALB/C 
mice 
--- Maryland, 
United States 
TB infection 
(aerosolized M. 
tuberculosis 
CDC1551 strain) 
Bacterial diversity c Stool 16S rRNA 
sequencing 
V1-V2 Pre- vs post-infection 
• Alpha diversity (Shannon diversity index): Post-
infection decrease (in all mice) 
• Beta diversity (PCoA; UniFrac): p < 0.001 
• 88 OTUs more abundant pre-infection: q < 0.01 
• Majority of differential OTUs: 
Firmicutes phyla 
• Relative species abundance of 
Lachnospiraceae and 
Ruminococcaceae and Bacteriodales 
order greater pre-infection and among 
controls 
30 
5 female 
BALB/C 
mice 
5 mice (1:1 
age-matched) 
TB infection 
(aerosolized M. 
tuberculosis  
H37Rv strain) 
TB vs Control 
• Differential clustering (PCoA; UniFrac distances): p 
< 0.001 
• 73 different OTUs: q < 0.01 
Case Study Patient with 
multi-drug 
resistant TB 
--- Marseille, 
France 
--- Microbial diversity Stool  16S and 18S 
rRNA 
sequencing; 
culture  
V6 • Depleted gut microbiota: 39 bacterial species, 18 phylotypes, 19 OTUs 
• Most phyla (from pyrosequencing) confirmed with culture (Firmicutes, Actinobacteria, 
Proteobacteria), except Fusobacteria species (only culture) and Cyanobacteria/Chloroplast (only 
pyrosequencing) 
• New species detected by culture (Candidatus “Paenibacillus antibioticophila”) and 18S rRNA 
sequencing (3 fungal species) 
31 
Case-Control 31 patients 
with 
pulmonary 
TB 
24 controls Shanghai, 
China 
TB status Bacterial diversity Sputum (cases); 
saliva / 
pharyngeal 
secretions 
(controls) 
16S rRNA 
sequencing  
V3 TB vs Control 
• Greater phyla and genera richness among patients with TB (24 phyla; 564 genera) vs controls (17 
phyla; 235 genera) 
• Most prevalent phyla: Firmicutes, Proteobacteria, Bacteriodetes, Crenarchaeota, and Actinobacteria 
• Lower Bacteriodetes and higher Actinobacteria prevalence 
32 
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• Certain genera (Stenotrophomonas, Cupriavidus, Pseudomonas, Thermus) and phyla (Aquificae, 
Planctomycetes) only in TB samples 
• Differential clustering (PCoA; UniFrac distances) 
32 patients 
with 
unilateral 
pulmonary 
TB 
24 healthy 
controls  
Jiangsu, 
China 
TB status Bacterial diversity Bronchoalveola
r lavage (cases); 
saliva, 
pharyngeal 
secretions 
(controls) 
16S rRNA 
sequencing  
V3 TB vs Control 
• Clustering (PCoA; UniFrac distances): Distinct 
• Genus: Most abundant genus differed 
 
TB (Uninfected vs Infected Lungs) 
• Clustering (PCoA; UniFrac distances): Similar 
• Genus: Mycobacteria and Porphyromonas abundances greater inside TB lesions 
• Shannon diversity index: Higher in bronchoalveolar lavage fluid from lungs with lesions, compared to 
controls 
36 
22 patients 
with TB 
14 controls 
with TB-like 
coughing 
Hong Kong 
SAR, China 
TB status Bacterial diversity Sputum  16S rRNA 
sequencing  
V1-V2 TB vs Control 
• Phyla: Lower Firmicutes, and higher Proteobacteria and Bacteriodetes abundance 
• Genra: Lower Streptococcus, and higher Neisseria and Prevotella  
• OTUs: 8 more prevalent, 2 less prevalent 
• No differences in clustering (PCoA; UniFrac distances) 
 
Overall 
• 98% of identified sequences accounted for 5 phyla (Proteobacteria, Firmicutes, Bacteriodetes, 
Fusobacteria, Actinobacteria) 
• Most prevalent bacterial genra: Neisseria, Prevotella, Streptococcus 
 
33 
Group 1: 
Newly 
diagnosed 
pulmonary 
Group 4: 
Healthy 
controls (n = 
20) 
Shanghai, 
China 
TB status Bacterial diversity Sputum (cases); 
throat swabs 
(controls) 
16S rRNA 
sequencing  
V1-V2 • Clustering (PCoA; UniFrac distances): Differed between Groups 1-3 vs 4; similar between Groups 1-3 
• Relative species abundance (phyla, genera): Heterogeneous between groups 
• Some genera (Bergeyella, Sharpea) only in Groups 1-3 
34 
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TB (n = 25) 
 
Group 2: 
Recurrent TB 
(n = 30) 
 
Group 3: 
Treatment 
failure (n = 
20) 
6 patients 
with TB 
6 controls 
without TB 
Medellìn, 
Colombia 
TB status Bacterial and fungi 
diversity 
Sputum, 
oropharyngeal, 
nasal samples 
16S rRNA 
sequencing 
(bacteria; 
fungi [fungal 
nuclear 
ribosomal 
internal 
transcribe 
spacer ITS1 
regions]) 
V1-V2 Bacteria: TB vs Control 
• Shannon diversity index: Bacterial diversity (in nasal samples) less diverse 
• Clustering (PCoA; UniFrac distances): Sputum and oropharyngeal samples clustered together, distinct 
from nasal samples 
• Oropharyngeal: Streptococcaceae more abundant 
 
Bacteria: Overall 
• Phyla: Relative abundance differed across sample type (bacterial diversity higher in sputum and lower 
in nasal samples) 
 
Fungi: TB vs Control 
• Genus: Cryptococcus (in oropharyngeal samples) significantly lower  
 
Fungi: Overall 
• Shannon diversity index: Fungal diversity greatest in nasal samples 
• Phyla: 90% sequences in Ascomycota and Basidiomycota; Ascomycota significantly differed between 
study participants 
35 
25 patients 16 controls Madhya TB status Bacterial diversity Sputum  16S rRNA V6-V7 TB vs Control 21 
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with 
pulmonary 
TB 
Pradesh, India sequencing  • Clustering (PCoA): Distinct 
• Phyla: Higher Firmicutes and Actinobacteria, lower Proteobacteria and Fusobateria 
• Most prevalent genera (cases: Streptococcus, Neisseria, Veillonella; controls: Gammaproteobacteria, 
Streptococcus, Neisseria, Haemophilus) 
• Species: Veillonella dispar and Rothia mucilaginosa greater 
• Shannon diversity index: Lower for TB (3.88; 602 OTUs) than controls (4.13; 490 OTUs) 
a PubMed search strategy was based on the following terms: “((microbiota[mesh] OR microbiota[tw] OR microbiome*[tw] OR virome*[tw] OR gut bacteria[tw]) AND (tuberculosis[mesh] OR tuberculosis[tw] OR 
TB[tw])),” and restricted by publication date (prior to June 6, 2016). Exclusion criteria included: 1) not primary data source (including reviews, editorials); 2) no whole microbiome sequencing techniques; 3) not 
among patients or animals with TB or exposure to TB (including assessing vaccine response among healthy volunteers, microbiome among patients with HIV or reproductive tract inflammation). Among the 44 
studies initially identified, 8 studies were within the scope of this review and included. 
b Assessed by 16S rRNA sequencing 
c First experiment: Baseline (pre-infection) to 179 days (post-infection). Second experiment: 0-46 days. 
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had more interferon gamma and Th1-like cytokines, compared to those without H. 
pylori.37 Actinobacteria in infant stool samples was associated with increased T cell 
responses to vaccination, including Bacille Calmette Guérin vaccination for TB.25 
Furthermore, cynomolgus macaques with H. pylori infection were less likely to develop 
active TB if inoculated with M. tuberculosis.37 Another murine study demonstrated how 
specific enteric bacteria (Helicobacter hepaticus) modulated the immune system to alter 
susceptibility to M. tuberculosis and vaccine response in a mouse model.38 One 
hypothesis was that activation of the innate immune system facilitates an enhanced 
response to other pathogens, such as M. tuberculosis. 
 
Several recent studies have provided evidence of the immunomodulatory mechanism of 
the gut microbiome, which produces short chain fatty acid (SCFA) metabolites that may 
affect the host response against M. tuberculosis.39 Intestinal microbiota produce SCFAs 
through the fermentation of resistant starches and dietary fiber.40 SCFAs have roles in 
host metabolism (as substrate for de novo lipid and glucose synthesis) and 
immunomodulation (through downregulating pro-inflammatory cytokines and Treg 
cells).41 In a study involving M. tuberculosis stimulation of human peripheral blood 
mononuclear cells, physiological concentrations of the SCFA butyrate significantly 
decreased pro-inflammatory cytokine production.39 Given the importance of the cell-
mediated response (including Treg cells 42) against TB infection, SCFA production is one 
hypothesized mechanism of the link between the microbiome and TB infection and 
disease. 
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Overall, the gut microbiome of TB samples had lower bacterial abundance and 
composition, relative to controls. However, given the limited data and heterogeneous 
study designs, preliminary evidence suggests the need for further studies to confirm 
etiology through mechanistic and clinical studies. Potential next steps include 
improving our understanding of the role of metabolites in mediating the association 
between the gut microbiome and TB disease and infection. 
 
Tuberculosis and the Lung Microbiome 
Several case-control studies in this review showed that bacterial diversity (richness, 
abundance, OTU clustering, Shannon index) in the respiratory tract differs between 
individuals with active TB, compared to controls (Table 25).21, 32, 33, 34, 36 Based on PCoA, 
four studies found distinct OTU clustering of sputum samples from study participants 
with TB disease, compared to controls.21, 32, 34, 36 However, one study observed no 
differences in OTU clustering.33 All case-control studies identified differences in 
bacterial richness or relative abundance, based on taxonomic categorizations (phyla, 
genus, species), in sputum from individuals with and without active TB. However, the 
specific differential taxonomic groups were inconsistent and not replicated across 
studies, which may reflect the relatively small and diverse sample populations.  
 
In 5 case-control studies, sputum was considered an indicator for the microbiome of the 
lung and lower respiratory tract among study participants with active TB. Given that 
sputum is likely to be contaminated by the upper respiratory tract during expectoration, 
the continued use of sputum reflects the challenge of directly obtaining samples from 
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the lung.  
 
Sample collection methods for referent groups varied, including samples from deep 
coughing of healthy individuals,32, 36 throat swabs,34 bronchoalveolar lavages,36 and 
sputum from individuals with TB-like coughing.33 Botero et al. (2014) reported that the 
microbial compositions of sputum and oropharyngeal samples were similar, which 
supports the use of throat swabs from controls.35 Limitations include: deep cough, throat 
swab, and sputum samples may represent the upper respiratory tract (instead of the lung 
and lower respiratory tract microbial composition); TB-like coughing could be caused 
by other diseases that affect the microbiome; and the invasiveness of bronchoalveolar 
lavages. Thus, interpretations of study findings need to account for potential sample 
contamination and the appropriate selection of controls. 
 
As a brief summary, several studies showed distinct bacterial richness or relative 
abundance of the lung microbiome among patients with active TB, compared to 
controls. Further studies are needed, particularly in light of differences in study designs 
and discrepant observations. 
 
Comparison of Study Methods  
Strengths of studies in this review included the consistent use of next-generation 
platforms for 16S ribosomal ribonucleic acid (rRNA) sequencing to assess the bacterial 
microbiome in all eight studies. Seven studies utilized 454 instruments (GS FLX, GS 
FLX-Titanium [Roche]), and one study used an Ion Torrent PGM (Thermo Fisher 
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Scientific). Two studies additionally evaluated fungal species,31, 35 and one study 
compared 16S rRNA results with culture and 18S rRNA sequencing.31 In all studies, 
sequence analyses were conducted through software (including Quantitative Insights 
Into Microbial Ecology, Mothur), and OTUs were identified through aligning sequences 
with reference databases (Ribosomal Database Project, Greengenes), in order to 
eliminate chimeras. Some studies considered differences (including sociodemographic 
characteristics) of sample populations, which are supported by previous literature. 
Additionally the eight studies included study participants from several geographic 
locations, which allowed for comparison and confirmation of similar findings across 
diverse populations. 
 
Available studies had several limitations, in addition to aforementioned challenges. 
Compared to Sanger sequencing (such as with ABI 3730 Genetic Analyzer [Applied 
Biosystems]), 454 sequencing has been reported to have higher error rates due to greater 
insertion and deletion rates.43 Importantly, methodological heterogeneity in data 
analyses rendered comparisons across studies difficult; these included differences in 
hypervariable regions (V1-V3, V6, V7), diversity indices (including alpha- [Shannon 
index, Chao1] and beta-diversity [unweighted and weighted UniFrac, Jaccard]), and 
additional analyses (PCoA, hierarchical clustering heatmap).  
 
Separately in the case-control studies, the sample sizes (12-95) and geographic locations 
(Asia [China, Hong Kong, India], South America [Colombia]) ranged widely. 
Therefore, results were difficult to generalize to other countries. Additionally, numerous 
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other potential confounding factors (antibiotic use [including anti-TB treatment], 
comorbidities, environmental factors, diet) were either unaccounted for or considered 
differently across study populations. Standard anti-TB medications are a combination 
of antibiotics, which are expected to alter the microbiome, and therefore need to be 
considered while interpreting study results. Four of the six case-control studies excluded 
participants with recent antibiotic use (one or three months prior to baseline).32, 33, 35, 36 
However, two studies did not report the exact length of time that participants did not 
receive antibiotics before sample collection,21 or prior antibiotic use.34 In the case report, 
the patient was receiving anti-TB treatment for multi-drug resistant TB at the time of 
sample collection.31 
 
DISCUSSION 
In this review, there is limited evidence regarding the key question of the bi-directional 
associations between TB infection and disease and the lung and gut microbiome. 
Potential mechanistic pathways need to be considered through epidemiological and 
mechanistic studies, including immunological, nutritional, metabolic and endocrine 
factors (Figure 5). Furthermore, there are a number of other research gaps and related 
questions that have not been directly addressed by studies to date. One of these 
overarching knowledge gaps involves inter-individual variability, which is a key focus 
area of the Human Microbiome Project.44 What is the extent that a core set of human 
microbiome genes or species is shared between individuals?44 Additionally, what are 
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Figure 5. Potential mechanistic pathways between the microbiome and TB 
the temporal changes of lung and gut microbiota (including throughout TB disease 
progression and treatment)? Separately, to what extent does crosstalk occur between the 
lung and gut microbiome, particularly in response to TB infection and disease-related  
perturbances? Followingly, do these interactions between the respiratory and 
gastrointestinal microbiome modulate immune responses to TB infection and disease?  
 
CONCLUSION 
 Based on preliminary evidence from studies in this review, the lung and gut 
microbiome were associated with TB infection and disease. The microbiome is a 
potential modifiable risk factor for TB infection and disease, however the number of 
available studies is limited. Most studies have focused on characterizing the microbial 
Figure 1. Potential mechanistic pathways between the microbiome and TB
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profile among individuals with and without active TB disease. Future studies are 
necessary to further elucidate etiology, key mechanisms, and potential clinical 
significance. Specifically, it is important to assess: 1) the sputum and gut microbiome 
as risk factors for TB infection and disease susceptibility, disease progression, and 
treatment outcomes; and 2) the effects of TB infection and disease on the sputum and 
gut microbiome, which can subsequently impact health via alteration of immune 
responses. 
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